Stacks.cdc.gov



Differential Gene Expression Elicited by Children in Response to the 2015-16 Live Attenuated versus Inactivated Influenza Vaccine Authors: Kelly Stefano Cole, PhD, 1 Judith M. Martin, MD, 2 William T. Horne, II, MS,2 Chyongchiou J. Lin, PhD, 3 Mary Patricia Nowalk, PhD, RD, 3 John F. Alcorn, PhD,2 Richard K. Zimmerman, MD, MPH, MA3Affiliations: 1Department of Immunology and Center for Vaccine Research; 2Department of Pediatrics; 3Department of Family Medicine, University of Pittsburgh, Pittsburgh, PA, USA Correspondence: Richard K. Zimmerman, MD, MPHUniversity of PittsburghDepartment of Family MedicineSuite 520 Schenley Place4420 Bayard StreetPittsburgh PA 15260zimmer@pitt.edu412/383-2354Word count: Text - 2520; Abstract - 230; Tables - 2; Figures – 1; Supplemental Tables – 2.Clinical Trial Registry: N/A AbstractBackground: In recent influenza seasons, the live attenuated influenza vaccine (LAIV) has not demonstrated the same level of vaccine effectiveness as that observed among children who received the inactivated influenza vaccine (IIV). To better understand this difference, this study compared the mRNA sequencing transcription profile (RNA seq) in children who received either IIV or LAIV.Methods: Children 3-17 years of age receiving quadrivalent influenza vaccine were enrolled. Blood samples were collected on Day 0 prior to vaccination and again on Day 7 (range 6-10 days) following vaccination. Total RNA was isolated from PAXgene tubes and sequenced for a custom panel of 89 transcripts using the TruSeq Targeted RNA Expression method. Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated, log2 transformed and compared between the two vaccine groups.Results: Of 72 children, 46 received IIV and 26 received LAIV. Following IIV vaccination, 7 genes demonstrated significant differential expression at Day 7 (down-regulated). In contrast, following LAIV vaccination, 8 genes demonstrated significant differential expression at Day 7 (5 up-regulated and 3 down-regulated). Only two genes demonstrated similar patterns of regulation in both groups. Conclusions: Differential regulation of genes was observed between 2015-16 LAIV and IIV recipients. These results help to elucidate the immune response to influenza vaccines and may be related to the difference in vaccine effectiveness observed in recent years between LAIV and IIV.Key Words: Influenza vaccine, antibodies, RNA sequencingINTRODUCTIONIn recent influenza seasons, the live attenuated influenza vaccine (LAIV) has offered limited protection from influenza to children in the United States (U.S.). Specifically, the vaccine effectiveness (VE) of LAIV against any influenza in children 2-17 years old was 7% (95%CI = -46 to 40%) in 2013-2014 PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYWdsYW5pPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjEyMDE8L1JlY051bT48RGlzcGxheVRleHQ+WzFdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjEyMDE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0i

MTQ1NTcyOTAzMiI+MTIwMTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

R2FnbGFuaSwgTS48L2F1dGhvcj48YXV0aG9yPlBydXN6eW5za2ksIEouPC9hdXRob3I+PGF1dGhv

cj5NdXJ0aHksIEsuPC9hdXRob3I+PGF1dGhvcj5DbGlwcGVyLCBMLjwvYXV0aG9yPjxhdXRob3I+

Um9iZXJ0c29uLCBBLjwvYXV0aG9yPjxhdXRob3I+UmVpcywgTS48L2F1dGhvcj48YXV0aG9yPkNo

dW5nLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+UGllZHJhLCBQLiBBLjwvYXV0aG9yPjxhdXRob3I+

QXZhZGhhbnVsYSwgVi48L2F1dGhvcj48YXV0aG9yPk5vd2FsaywgTS4gUC48L2F1dGhvcj48YXV0

aG9yPlppbW1lcm1hbiwgUi4gSy48L2F1dGhvcj48YXV0aG9yPkphY2tzb24sIE0uIEwuPC9hdXRo

b3I+PGF1dGhvcj5KYWNrc29uLCBMLiBBLjwvYXV0aG9yPjxhdXRob3I+UGV0cmllLCBKLiBHLjwv

YXV0aG9yPjxhdXRob3I+T2htaXQsIFMuIEUuPC9hdXRob3I+PGF1dGhvcj5Nb250bywgQS4gUy48

L2F1dGhvcj48YXV0aG9yPk1jTGVhbiwgSC4gUS48L2F1dGhvcj48YXV0aG9yPkJlbG9uZ2lhLCBF

LiBBLjwvYXV0aG9yPjxhdXRob3I+RnJ5LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+Rmxhbm5lcnks

IEIuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+QmF5bG9y

IFNjb3R0ICZhbXA7IFdoaXRlIEhlYWx0aCwgVGV4YXMgQSZhbXA7TSBIZWFsdGggU2NpZW5jZSBD

ZW50ZXIgQ29sbGVnZSBvZiBNZWRpY2luZSwgVGVtcGxlLiYjeEQ7Q2VudGVycyBmb3IgRGlzZWFz

ZSBDb250cm9sIGFuZCBQcmV2ZW50aW9uLCBBdGxhbnRhLCBHZW9yZ2lhLiYjeEQ7QmF5bG9yIENv

bGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLiYjeEQ7VW5pdmVyc2l0eSBvZiBQaXR0

c2J1cmdoLCBQZW5uc3lsdmFuaWEuJiN4RDtHcm91cCBIZWFsdGggUmVzZWFyY2ggSW5zdGl0dXRl

LCBTZWF0dGxlLCBXYXNoaW5ndG9uLiYjeEQ7RGVwYXJ0bWVudCBvZiBFcGlkZW1pb2xvZ3ksIFVu

aXZlcnNpdHkgb2YgTWljaGlnYW4gU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIEFubiBBcmJvci4m

I3hEO01hcnNoZmllbGQgQ2xpbmljIFJlc2VhcmNoIEZvdW5kYXRpb24sIFdpc2NvbnNpbi48L2F1

dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5JbmZsdWVuemEgVmFjY2luZSBFZmZlY3RpdmVuZXNz

IEFnYWluc3QgMjAwOSBQYW5kZW1pYyBJbmZsdWVuemEgQShIMU4xKSBWaXJ1cyBEaWZmZXJlZCBi

eSBWYWNjaW5lIFR5cGUgRHVyaW5nIDIwMTMtMjAxNCBpbiB0aGUgVW5pdGVkIFN0YXRlczwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5KIEluZmVjdCBEaXM8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPlRoZSBKb3VybmFsIG9mIGluZmVjdGlvdXMgZGlzZWFzZXM8L2FsdC10aXRsZT48L3RpdGxl

cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9wZXJpb2RpY2Fs

PjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFi

YnItMT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9hbHQtcGVy

aW9kaWNhbD48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbiA2PC9k

YXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzNy02NjEzIChFbGVjdHJvbmljKSYjeEQ7

MDAyMi0xODk5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNjc0Mzg0MjwvYWNjZXNz

aW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWgu

Z292L3B1Ym1lZC8yNjc0Mzg0MjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+MTAuMTA5My9pbmZkaXMvaml2NTc3PC9lbGVjdHJvbmljLXJlc291cmNl

LW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYWdsYW5pPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjEyMDE8L1JlY051bT48RGlzcGxheVRleHQ+WzFdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjEyMDE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0i

MTQ1NTcyOTAzMiI+MTIwMTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

R2FnbGFuaSwgTS48L2F1dGhvcj48YXV0aG9yPlBydXN6eW5za2ksIEouPC9hdXRob3I+PGF1dGhv

cj5NdXJ0aHksIEsuPC9hdXRob3I+PGF1dGhvcj5DbGlwcGVyLCBMLjwvYXV0aG9yPjxhdXRob3I+

Um9iZXJ0c29uLCBBLjwvYXV0aG9yPjxhdXRob3I+UmVpcywgTS48L2F1dGhvcj48YXV0aG9yPkNo

dW5nLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+UGllZHJhLCBQLiBBLjwvYXV0aG9yPjxhdXRob3I+

QXZhZGhhbnVsYSwgVi48L2F1dGhvcj48YXV0aG9yPk5vd2FsaywgTS4gUC48L2F1dGhvcj48YXV0

aG9yPlppbW1lcm1hbiwgUi4gSy48L2F1dGhvcj48YXV0aG9yPkphY2tzb24sIE0uIEwuPC9hdXRo

b3I+PGF1dGhvcj5KYWNrc29uLCBMLiBBLjwvYXV0aG9yPjxhdXRob3I+UGV0cmllLCBKLiBHLjwv

YXV0aG9yPjxhdXRob3I+T2htaXQsIFMuIEUuPC9hdXRob3I+PGF1dGhvcj5Nb250bywgQS4gUy48

L2F1dGhvcj48YXV0aG9yPk1jTGVhbiwgSC4gUS48L2F1dGhvcj48YXV0aG9yPkJlbG9uZ2lhLCBF

LiBBLjwvYXV0aG9yPjxhdXRob3I+RnJ5LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+Rmxhbm5lcnks

IEIuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+QmF5bG9y

IFNjb3R0ICZhbXA7IFdoaXRlIEhlYWx0aCwgVGV4YXMgQSZhbXA7TSBIZWFsdGggU2NpZW5jZSBD

ZW50ZXIgQ29sbGVnZSBvZiBNZWRpY2luZSwgVGVtcGxlLiYjeEQ7Q2VudGVycyBmb3IgRGlzZWFz

ZSBDb250cm9sIGFuZCBQcmV2ZW50aW9uLCBBdGxhbnRhLCBHZW9yZ2lhLiYjeEQ7QmF5bG9yIENv

bGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLiYjeEQ7VW5pdmVyc2l0eSBvZiBQaXR0

c2J1cmdoLCBQZW5uc3lsdmFuaWEuJiN4RDtHcm91cCBIZWFsdGggUmVzZWFyY2ggSW5zdGl0dXRl

LCBTZWF0dGxlLCBXYXNoaW5ndG9uLiYjeEQ7RGVwYXJ0bWVudCBvZiBFcGlkZW1pb2xvZ3ksIFVu

aXZlcnNpdHkgb2YgTWljaGlnYW4gU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIEFubiBBcmJvci4m

I3hEO01hcnNoZmllbGQgQ2xpbmljIFJlc2VhcmNoIEZvdW5kYXRpb24sIFdpc2NvbnNpbi48L2F1

dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5JbmZsdWVuemEgVmFjY2luZSBFZmZlY3RpdmVuZXNz

IEFnYWluc3QgMjAwOSBQYW5kZW1pYyBJbmZsdWVuemEgQShIMU4xKSBWaXJ1cyBEaWZmZXJlZCBi

eSBWYWNjaW5lIFR5cGUgRHVyaW5nIDIwMTMtMjAxNCBpbiB0aGUgVW5pdGVkIFN0YXRlczwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5KIEluZmVjdCBEaXM8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPlRoZSBKb3VybmFsIG9mIGluZmVjdGlvdXMgZGlzZWFzZXM8L2FsdC10aXRsZT48L3RpdGxl

cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9wZXJpb2RpY2Fs

PjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFi

YnItMT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9hbHQtcGVy

aW9kaWNhbD48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbiA2PC9k

YXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzNy02NjEzIChFbGVjdHJvbmljKSYjeEQ7

MDAyMi0xODk5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNjc0Mzg0MjwvYWNjZXNz

aW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWgu

Z292L3B1Ym1lZC8yNjc0Mzg0MjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+MTAuMTA5My9pbmZkaXMvaml2NTc3PC9lbGVjdHJvbmljLXJlc291cmNl

LW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA [1] and 26% (95%CI = 3 to 44) in 2014-2015 ADDIN EN.CITE <EndNote><Cite><Author>Zimmerman</Author><Year>2016</Year><RecNum>26</RecNum><DisplayText>[2]</DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181828">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Zimmerman, Richard K</author><author>Nowalk, Mary Patricia</author><author>Chung, Jessie</author><author>Jackson, Michael L</author><author>Jackson, Lisa A</author><author>Petrie, Joshua G</author><author>Monto, Arnold S</author><author>McLean, Huong Q</author><author>Belongia, Edward A</author><author>Gaglani, Manjusha</author></authors></contributors><titles><title>2014–2015 influenza vaccine effectiveness in the United States by vaccine type</title><secondary-title>Clinical Infectious Diseases</secondary-title></titles><periodical><full-title>Clinical Infectious Diseases</full-title></periodical><pages>1564-1573</pages><volume>63</volume><number>12</number><dates><year>2016</year></dates><isbn>1058-4838</isbn><urls></urls><custom2>PMC5146719</custom2></record></Cite></EndNote>[2]. LAIV’s VE against influenza A/H3N2 was especially low among children 2-17 years in 2014-2015 (-6% VE; 95%CI = -40% to 20%), while LAIV offered reasonable protection (74% VE (95%CI= 25% to 91%)) against the less commonly occurring influenza B ADDIN EN.CITE <EndNote><Cite><Author>Zimmerman</Author><Year>2016</Year><RecNum>26</RecNum><DisplayText>[2]</DisplayText><record><rec-number>26</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181828">26</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Zimmerman, Richard K</author><author>Nowalk, Mary Patricia</author><author>Chung, Jessie</author><author>Jackson, Michael L</author><author>Jackson, Lisa A</author><author>Petrie, Joshua G</author><author>Monto, Arnold S</author><author>McLean, Huong Q</author><author>Belongia, Edward A</author><author>Gaglani, Manjusha</author></authors></contributors><titles><title>2014–2015 influenza vaccine effectiveness in the United States by vaccine type</title><secondary-title>Clinical Infectious Diseases</secondary-title></titles><periodical><full-title>Clinical Infectious Diseases</full-title></periodical><pages>1564-1573</pages><volume>63</volume><number>12</number><dates><year>2016</year></dates><isbn>1058-4838</isbn><urls></urls><custom2>PMC5146719</custom2></record></Cite></EndNote>[2]. In the prior (2013–2014) season, VE of LAIV against (A/H1N1) was poor PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYWdsYW5pPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjEyMDE8L1JlY051bT48RGlzcGxheVRleHQ+WzFdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjEyMDE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0i

MTQ1NTcyOTAzMiI+MTIwMTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

R2FnbGFuaSwgTS48L2F1dGhvcj48YXV0aG9yPlBydXN6eW5za2ksIEouPC9hdXRob3I+PGF1dGhv

cj5NdXJ0aHksIEsuPC9hdXRob3I+PGF1dGhvcj5DbGlwcGVyLCBMLjwvYXV0aG9yPjxhdXRob3I+

Um9iZXJ0c29uLCBBLjwvYXV0aG9yPjxhdXRob3I+UmVpcywgTS48L2F1dGhvcj48YXV0aG9yPkNo

dW5nLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+UGllZHJhLCBQLiBBLjwvYXV0aG9yPjxhdXRob3I+

QXZhZGhhbnVsYSwgVi48L2F1dGhvcj48YXV0aG9yPk5vd2FsaywgTS4gUC48L2F1dGhvcj48YXV0

aG9yPlppbW1lcm1hbiwgUi4gSy48L2F1dGhvcj48YXV0aG9yPkphY2tzb24sIE0uIEwuPC9hdXRo

b3I+PGF1dGhvcj5KYWNrc29uLCBMLiBBLjwvYXV0aG9yPjxhdXRob3I+UGV0cmllLCBKLiBHLjwv

YXV0aG9yPjxhdXRob3I+T2htaXQsIFMuIEUuPC9hdXRob3I+PGF1dGhvcj5Nb250bywgQS4gUy48

L2F1dGhvcj48YXV0aG9yPk1jTGVhbiwgSC4gUS48L2F1dGhvcj48YXV0aG9yPkJlbG9uZ2lhLCBF

LiBBLjwvYXV0aG9yPjxhdXRob3I+RnJ5LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+Rmxhbm5lcnks

IEIuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+QmF5bG9y

IFNjb3R0ICZhbXA7IFdoaXRlIEhlYWx0aCwgVGV4YXMgQSZhbXA7TSBIZWFsdGggU2NpZW5jZSBD

ZW50ZXIgQ29sbGVnZSBvZiBNZWRpY2luZSwgVGVtcGxlLiYjeEQ7Q2VudGVycyBmb3IgRGlzZWFz

ZSBDb250cm9sIGFuZCBQcmV2ZW50aW9uLCBBdGxhbnRhLCBHZW9yZ2lhLiYjeEQ7QmF5bG9yIENv

bGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLiYjeEQ7VW5pdmVyc2l0eSBvZiBQaXR0

c2J1cmdoLCBQZW5uc3lsdmFuaWEuJiN4RDtHcm91cCBIZWFsdGggUmVzZWFyY2ggSW5zdGl0dXRl

LCBTZWF0dGxlLCBXYXNoaW5ndG9uLiYjeEQ7RGVwYXJ0bWVudCBvZiBFcGlkZW1pb2xvZ3ksIFVu

aXZlcnNpdHkgb2YgTWljaGlnYW4gU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIEFubiBBcmJvci4m

I3hEO01hcnNoZmllbGQgQ2xpbmljIFJlc2VhcmNoIEZvdW5kYXRpb24sIFdpc2NvbnNpbi48L2F1

dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5JbmZsdWVuemEgVmFjY2luZSBFZmZlY3RpdmVuZXNz

IEFnYWluc3QgMjAwOSBQYW5kZW1pYyBJbmZsdWVuemEgQShIMU4xKSBWaXJ1cyBEaWZmZXJlZCBi

eSBWYWNjaW5lIFR5cGUgRHVyaW5nIDIwMTMtMjAxNCBpbiB0aGUgVW5pdGVkIFN0YXRlczwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5KIEluZmVjdCBEaXM8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPlRoZSBKb3VybmFsIG9mIGluZmVjdGlvdXMgZGlzZWFzZXM8L2FsdC10aXRsZT48L3RpdGxl

cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9wZXJpb2RpY2Fs

PjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFi

YnItMT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9hbHQtcGVy

aW9kaWNhbD48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbiA2PC9k

YXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzNy02NjEzIChFbGVjdHJvbmljKSYjeEQ7

MDAyMi0xODk5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNjc0Mzg0MjwvYWNjZXNz

aW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWgu

Z292L3B1Ym1lZC8yNjc0Mzg0MjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+MTAuMTA5My9pbmZkaXMvaml2NTc3PC9lbGVjdHJvbmljLXJlc291cmNl

LW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYWdsYW5pPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48

UmVjTnVtPjEyMDE8L1JlY051bT48RGlzcGxheVRleHQ+WzFdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjEyMDE8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0i

MTQ1NTcyOTAzMiI+MTIwMTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

R2FnbGFuaSwgTS48L2F1dGhvcj48YXV0aG9yPlBydXN6eW5za2ksIEouPC9hdXRob3I+PGF1dGhv

cj5NdXJ0aHksIEsuPC9hdXRob3I+PGF1dGhvcj5DbGlwcGVyLCBMLjwvYXV0aG9yPjxhdXRob3I+

Um9iZXJ0c29uLCBBLjwvYXV0aG9yPjxhdXRob3I+UmVpcywgTS48L2F1dGhvcj48YXV0aG9yPkNo

dW5nLCBKLiBSLjwvYXV0aG9yPjxhdXRob3I+UGllZHJhLCBQLiBBLjwvYXV0aG9yPjxhdXRob3I+

QXZhZGhhbnVsYSwgVi48L2F1dGhvcj48YXV0aG9yPk5vd2FsaywgTS4gUC48L2F1dGhvcj48YXV0

aG9yPlppbW1lcm1hbiwgUi4gSy48L2F1dGhvcj48YXV0aG9yPkphY2tzb24sIE0uIEwuPC9hdXRo

b3I+PGF1dGhvcj5KYWNrc29uLCBMLiBBLjwvYXV0aG9yPjxhdXRob3I+UGV0cmllLCBKLiBHLjwv

YXV0aG9yPjxhdXRob3I+T2htaXQsIFMuIEUuPC9hdXRob3I+PGF1dGhvcj5Nb250bywgQS4gUy48

L2F1dGhvcj48YXV0aG9yPk1jTGVhbiwgSC4gUS48L2F1dGhvcj48YXV0aG9yPkJlbG9uZ2lhLCBF

LiBBLjwvYXV0aG9yPjxhdXRob3I+RnJ5LCBBLiBNLjwvYXV0aG9yPjxhdXRob3I+Rmxhbm5lcnks

IEIuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+QmF5bG9y

IFNjb3R0ICZhbXA7IFdoaXRlIEhlYWx0aCwgVGV4YXMgQSZhbXA7TSBIZWFsdGggU2NpZW5jZSBD

ZW50ZXIgQ29sbGVnZSBvZiBNZWRpY2luZSwgVGVtcGxlLiYjeEQ7Q2VudGVycyBmb3IgRGlzZWFz

ZSBDb250cm9sIGFuZCBQcmV2ZW50aW9uLCBBdGxhbnRhLCBHZW9yZ2lhLiYjeEQ7QmF5bG9yIENv

bGxlZ2Ugb2YgTWVkaWNpbmUsIEhvdXN0b24sIFRleGFzLiYjeEQ7VW5pdmVyc2l0eSBvZiBQaXR0

c2J1cmdoLCBQZW5uc3lsdmFuaWEuJiN4RDtHcm91cCBIZWFsdGggUmVzZWFyY2ggSW5zdGl0dXRl

LCBTZWF0dGxlLCBXYXNoaW5ndG9uLiYjeEQ7RGVwYXJ0bWVudCBvZiBFcGlkZW1pb2xvZ3ksIFVu

aXZlcnNpdHkgb2YgTWljaGlnYW4gU2Nob29sIG9mIFB1YmxpYyBIZWFsdGgsIEFubiBBcmJvci4m

I3hEO01hcnNoZmllbGQgQ2xpbmljIFJlc2VhcmNoIEZvdW5kYXRpb24sIFdpc2NvbnNpbi48L2F1

dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5JbmZsdWVuemEgVmFjY2luZSBFZmZlY3RpdmVuZXNz

IEFnYWluc3QgMjAwOSBQYW5kZW1pYyBJbmZsdWVuemEgQShIMU4xKSBWaXJ1cyBEaWZmZXJlZCBi

eSBWYWNjaW5lIFR5cGUgRHVyaW5nIDIwMTMtMjAxNCBpbiB0aGUgVW5pdGVkIFN0YXRlczwvdGl0

bGU+PHNlY29uZGFyeS10aXRsZT5KIEluZmVjdCBEaXM8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPlRoZSBKb3VybmFsIG9mIGluZmVjdGlvdXMgZGlzZWFzZXM8L2FsdC10aXRsZT48L3RpdGxl

cz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9wZXJpb2RpY2Fs

PjxhbHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFi

YnItMT5UaGUgSm91cm5hbCBvZiBpbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9hbHQtcGVy

aW9kaWNhbD48ZGF0ZXM+PHllYXI+MjAxNjwveWVhcj48cHViLWRhdGVzPjxkYXRlPkphbiA2PC9k

YXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzNy02NjEzIChFbGVjdHJvbmljKSYjeEQ7

MDAyMi0xODk5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNjc0Mzg0MjwvYWNjZXNz

aW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWgu

Z292L3B1Ym1lZC8yNjc0Mzg0MjwvdXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25p

Yy1yZXNvdXJjZS1udW0+MTAuMTA5My9pbmZkaXMvaml2NTc3PC9lbGVjdHJvbmljLXJlc291cmNl

LW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA [1], but influenza A/H1N1 did not circulate widely in 2014-15, thus VE was not calculated. The reason for the reported decline in LAIV VE from previous seasons PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5PaG1pdDwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl

Y051bT43NDwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMywgNF08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+NzQ8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSJ3cmQwZnNwejlkenM5cGVkdnIyeDB4eGZ0ZDJmcnMwdnh2NXoiIHRpbWVzdGFtcD0iMTUw

MTUyOTEyOCI+NzQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk9obWl0

LCBTLiBFLjwvYXV0aG9yPjxhdXRob3I+VGhvbXBzb24sIE0uIEcuPC9hdXRob3I+PGF1dGhvcj5Q

ZXRyaWUsIEouIEcuPC9hdXRob3I+PGF1dGhvcj5UaGFrZXIsIFMuIE4uPC9hdXRob3I+PGF1dGhv

cj5KYWNrc29uLCBNLiBMLjwvYXV0aG9yPjxhdXRob3I+QmVsb25naWEsIEUuIEEuPC9hdXRob3I+

PGF1dGhvcj5aaW1tZXJtYW4sIFIuIEsuPC9hdXRob3I+PGF1dGhvcj5HYWdsYW5pLCBNLjwvYXV0

aG9yPjxhdXRob3I+TGFtZXJhdG8sIEwuPC9hdXRob3I+PGF1dGhvcj5TcGVuY2VyLCBTLiBNLjwv

YXV0aG9yPjxhdXRob3I+SmFja3NvbiwgTC48L2F1dGhvcj48YXV0aG9yPk1lZWNlLCBKLiBLLjwv

YXV0aG9yPjxhdXRob3I+Tm93YWxrLCBNLiBQLjwvYXV0aG9yPjxhdXRob3I+U29uZywgSi48L2F1

dGhvcj48YXV0aG9yPlplcnZvcywgTS48L2F1dGhvcj48YXV0aG9yPkNoZW5nLCBQLiBZLjwvYXV0

aG9yPjxhdXRob3I+UmluYWxkbywgQy4gUi48L2F1dGhvcj48YXV0aG9yPkNsaXBwZXIsIEwuPC9h

dXRob3I+PGF1dGhvcj5TaGF5LCBELiBLLjwvYXV0aG9yPjxhdXRob3I+UGllZHJhLCBQLjwvYXV0

aG9yPjxhdXRob3I+TW9udG8sIEEuIFMuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz

PjxhdXRoLWFkZHJlc3M+T2htaXQsIFNFJiN4RDtVbml2IE1pY2hpZ2FuLCBTY2ggUHVibCBIbHRo

LCAxNDE1IFdhc2hpbmd0b24gSHRzLCBBbm4gQXJib3IsIE1JIDQ4MTA5IFVTQSYjeEQ7VW5pdiBN

aWNoaWdhbiwgU2NoIFB1YmwgSGx0aCwgMTQxNSBXYXNoaW5ndG9uIEh0cywgQW5uIEFyYm9yLCBN

SSA0ODEwOSBVU0EmI3hEO1VuaXYgTWljaGlnYW4sIFNjaCBQdWJsIEhsdGgsIERlcHQgRXBpZGVt

aW9sLCBBbm4gQXJib3IsIE1JIDQ4MTA5IFVTQSYjeEQ7Q3RyIERpcyBDb250cm9sICZhbXA7IFBy

ZXZlbnQsIEluZmx1ZW56YSBEaXYsIEF0bGFudGEsIEdBIFVTQSYjeEQ7R3JwIEhsdGggUmVzIElu

c3QsIFNlYXR0bGUsIFdBIFVTQSYjeEQ7TWFyc2hmaWVsZCBDbGluIFJlcyBGZG4sIE1hcnNoZmll

bGQsIFdJIFVTQSYjeEQ7VW5pdiBQaXR0c2J1cmdoLCBEZXB0IEZhbWlseSBNZWQsIFBpdHRzYnVy

Z2gsIFBBIDE1MjYwIFVTQSYjeEQ7VW5pdiBQaXR0c2J1cmdoLCBEZXB0IFBhdGhvbCwgUGl0dHNi

dXJnaCwgUEEgMTUyNjAgVVNBJiN4RDtTY290dCAmYW1wOyBXaGl0ZSBIZWFsdGhjYXJlLCBUZW1w

bGUsIFRYIFVTQSYjeEQ7VGV4YXMgQSZhbXA7TSBIbHRoIFNjaSBDdHIsIENvbGwgTWVkLCBUZW1w

bGUsIFRYIFVTQSYjeEQ7SGVucnkgRm9yZCBIbHRoIFN5c3QsIERldHJvaXQsIE1JIFVTQSYjeEQ7

QmF5bG9yIENvbGwgTWVkLCBIb3VzdG9uLCBUWCA3NzAzMCBVU0E8L2F1dGgtYWRkcmVzcz48dGl0

bGVzPjx0aXRsZT5JbmZsdWVuemEgVmFjY2luZSBFZmZlY3RpdmVuZXNzIGluIHRoZSAyMDExLTIw

MTIgU2Vhc29uOiBQcm90ZWN0aW9uIEFnYWluc3QgRWFjaCBDaXJjdWxhdGluZyBWaXJ1cyBhbmQg

dGhlIEVmZmVjdCBvZiBQcmlvciBWYWNjaW5hdGlvbiBvbiBFc3RpbWF0ZXM8L3RpdGxlPjxzZWNv

bmRhcnktdGl0bGU+Q2xpbmljYWwgSW5mZWN0aW91cyBEaXNlYXNlczwvc2Vjb25kYXJ5LXRpdGxl

PjxhbHQtdGl0bGU+Q2xpbiBJbmZlY3QgRGlzPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+Q2xpbmljYWwgSW5mZWN0aW91cyBEaXNlYXNlczwvZnVsbC10aXRsZT48

L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNsaW4gSW5mZWN0IERpczwv

ZnVsbC10aXRsZT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zMTktMzI3PC9wYWdlcz48dm9sdW1l

PjU4PC92b2x1bWU+PG51bWJlcj4zPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPmluZmx1ZW56

YTwva2V5d29yZD48a2V5d29yZD5tZWRpY2FsbHkgYXR0ZW5kZWQgaW5mbHVlbnphPC9rZXl3b3Jk

PjxrZXl3b3JkPnZhY2NpbmUgZWZmZWN0aXZlbmVzczwva2V5d29yZD48a2V5d29yZD5hbWJ1bGF0

b3J5IGNhcmU8L2tleXdvcmQ+PGtleXdvcmQ+aW1tdW5pemF0aW9uIHByYWN0aWNlcyBhY2lwPC9r

ZXl3b3JkPjxrZXl3b3JkPmFkdmlzb3J5LWNvbW1pdHRlZTwva2V5d29yZD48a2V5d29yZD51bml0

ZWQtc3RhdGVzPC9rZXl3b3JkPjxrZXl3b3JkPmVmZmljYWN5PC9rZXl3b3JkPjxrZXl3b3JkPnJl

Y29tbWVuZGF0aW9uczwva2V5d29yZD48a2V5d29yZD5pbW11bm9nZW5pY2l0eTwva2V5d29yZD48

a2V5d29yZD5wcmV2ZW50aW9uPC9rZXl3b3JkPjxrZXl3b3JkPmFudGlib2R5PC9rZXl3b3JkPjxr

ZXl3b3JkPmNoaWxkcmVuPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3ll

YXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWIgMTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjEwNTgtNDgzODwvaXNibj48YWNjZXNzaW9uLW51bT5XT1M6MDAwMzMwNDM1OTAwMDAzPC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD4mbHQ7R28gdG8gSVNJJmd0OzovL1dP

UzowMDAzMzA0MzU5MDAwMDM8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1D

SUQ6IFBNQzQwMDcxMTE7IFBNSUQ6IDI0MjM1MjY1IDwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNv

dXJjZS1udW0+RG9pIDEwLjEwOTMvQ2lkL0NpdDczNjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+

PGxhbmd1YWdlPkVuZ2xpc2g8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9y

Pk9zdGVyaG9sbTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051bT40NTA8L1JlY051bT48

cmVjb3JkPjxyZWMtbnVtYmVyPjQ1MDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBw

PSJFTiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0

YW1wPSIxNDA5MzM4Mjg1Ij40NTA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

Sm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0

aG9yPk9zdGVyaG9sbSwgTS4gVC48L2F1dGhvcj48YXV0aG9yPktlbGxleSwgTi4gUy48L2F1dGhv

cj48YXV0aG9yPlNvbW1lciwgQS48L2F1dGhvcj48YXV0aG9yPkJlbG9uZ2lhLCBFLiBBLjwvYXV0

aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkNlbnRlciBmb3IgSW5m

ZWN0aW91cyBEaXNlYXNlIFJlc2VhcmNoIGFuZCBQb2xpY3ksIFVuaXZlcnNpdHkgb2YgTWlubmVz

b3RhLCBNTiA1NTQ1NSwgVVNBLiBtdG9AdW1uLmVkdTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRp

dGxlPkVmZmljYWN5IGFuZCBlZmZlY3RpdmVuZXNzIG9mIGluZmx1ZW56YSB2YWNjaW5lczogYSBz

eXN0ZW1hdGljIHJldmlldyBhbmQgbWV0YS1hbmFseXNpczwvdGl0bGU+PHNlY29uZGFyeS10aXRs

ZT5MYW5jZXQgSW5mZWN0IERpczwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhlIExhbmNl

dC4gSW5mZWN0aW91cyBkaXNlYXNlczwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPkxhbmNldCBJbmZlY3QgRGlzPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIExhbmNl

dC4gSW5mZWN0aW91cyBkaXNlYXNlczwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+TGFuY2V0IEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUg

TGFuY2V0LiBJbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFn

ZXM+MzYtNDQ8L3BhZ2VzPjx2b2x1bWU+MTI8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5

d29yZHM+PGtleXdvcmQ+QWRvbGVzY2VudDwva2V5d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29y

ZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3Jk

PkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkluZmx1ZW56YSBBIFZpcnVzLCBIMU4xIFN1YnR5cGUvaW1tdW5vbG9neTwva2V5d29yZD48

a2V5d29yZD5JbmZsdWVuemEgVmFjY2luZXMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5

d29yZD5JbmZsdWVuemEsIEh1bWFuL2ltbXVub2xvZ3kvKnByZXZlbnRpb24gJmFtcDsgY29udHJv

bDwva2V5d29yZD48a2V5d29yZD5JbmZsdWVuemF2aXJ1cyBBLyppbW11bm9sb2d5PC9rZXl3b3Jk

PjxrZXl3b3JkPkluZmx1ZW56YXZpcnVzIEIvKmltbXVub2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+

TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+UGFuZGVtaWNzL3ByZXZlbnRpb24gJmFtcDsg

Y29udHJvbDwva2V5d29yZD48a2V5d29yZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFz

IFRvcGljPC9rZXl3b3JkPjxrZXl3b3JkPlNlYXNvbnM8L2tleXdvcmQ+PGtleXdvcmQ+VmFjY2lu

ZXMsIEluYWN0aXZhdGVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5Zb3VuZyBB

ZHVsdDwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEyPC95ZWFyPjxwdWItZGF0

ZXM+PGRhdGU+SmFuPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ3NC00NDU3IChF

bGVjdHJvbmljKSYjeEQ7MTQ3My0zMDk5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4y

MjAzMjg0NDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3

dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMjAzMjg0NDwvdXJsPjwvcmVsYXRlZC11cmxzPjwv

dXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9TMTQ3My0zMDk5KDExKTcwMjk1

LVg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5PaG1pdDwvQXV0aG9yPjxZZWFyPjIwMTQ8L1llYXI+PFJl

Y051bT43NDwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMywgNF08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+NzQ8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSJ3cmQwZnNwejlkenM5cGVkdnIyeDB4eGZ0ZDJmcnMwdnh2NXoiIHRpbWVzdGFtcD0iMTUw

MTUyOTEyOCI+NzQ8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPk9obWl0

LCBTLiBFLjwvYXV0aG9yPjxhdXRob3I+VGhvbXBzb24sIE0uIEcuPC9hdXRob3I+PGF1dGhvcj5Q

ZXRyaWUsIEouIEcuPC9hdXRob3I+PGF1dGhvcj5UaGFrZXIsIFMuIE4uPC9hdXRob3I+PGF1dGhv

cj5KYWNrc29uLCBNLiBMLjwvYXV0aG9yPjxhdXRob3I+QmVsb25naWEsIEUuIEEuPC9hdXRob3I+

PGF1dGhvcj5aaW1tZXJtYW4sIFIuIEsuPC9hdXRob3I+PGF1dGhvcj5HYWdsYW5pLCBNLjwvYXV0

aG9yPjxhdXRob3I+TGFtZXJhdG8sIEwuPC9hdXRob3I+PGF1dGhvcj5TcGVuY2VyLCBTLiBNLjwv

YXV0aG9yPjxhdXRob3I+SmFja3NvbiwgTC48L2F1dGhvcj48YXV0aG9yPk1lZWNlLCBKLiBLLjwv

YXV0aG9yPjxhdXRob3I+Tm93YWxrLCBNLiBQLjwvYXV0aG9yPjxhdXRob3I+U29uZywgSi48L2F1

dGhvcj48YXV0aG9yPlplcnZvcywgTS48L2F1dGhvcj48YXV0aG9yPkNoZW5nLCBQLiBZLjwvYXV0

aG9yPjxhdXRob3I+UmluYWxkbywgQy4gUi48L2F1dGhvcj48YXV0aG9yPkNsaXBwZXIsIEwuPC9h

dXRob3I+PGF1dGhvcj5TaGF5LCBELiBLLjwvYXV0aG9yPjxhdXRob3I+UGllZHJhLCBQLjwvYXV0

aG9yPjxhdXRob3I+TW9udG8sIEEuIFMuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3Jz

PjxhdXRoLWFkZHJlc3M+T2htaXQsIFNFJiN4RDtVbml2IE1pY2hpZ2FuLCBTY2ggUHVibCBIbHRo

LCAxNDE1IFdhc2hpbmd0b24gSHRzLCBBbm4gQXJib3IsIE1JIDQ4MTA5IFVTQSYjeEQ7VW5pdiBN

aWNoaWdhbiwgU2NoIFB1YmwgSGx0aCwgMTQxNSBXYXNoaW5ndG9uIEh0cywgQW5uIEFyYm9yLCBN

SSA0ODEwOSBVU0EmI3hEO1VuaXYgTWljaGlnYW4sIFNjaCBQdWJsIEhsdGgsIERlcHQgRXBpZGVt

aW9sLCBBbm4gQXJib3IsIE1JIDQ4MTA5IFVTQSYjeEQ7Q3RyIERpcyBDb250cm9sICZhbXA7IFBy

ZXZlbnQsIEluZmx1ZW56YSBEaXYsIEF0bGFudGEsIEdBIFVTQSYjeEQ7R3JwIEhsdGggUmVzIElu

c3QsIFNlYXR0bGUsIFdBIFVTQSYjeEQ7TWFyc2hmaWVsZCBDbGluIFJlcyBGZG4sIE1hcnNoZmll

bGQsIFdJIFVTQSYjeEQ7VW5pdiBQaXR0c2J1cmdoLCBEZXB0IEZhbWlseSBNZWQsIFBpdHRzYnVy

Z2gsIFBBIDE1MjYwIFVTQSYjeEQ7VW5pdiBQaXR0c2J1cmdoLCBEZXB0IFBhdGhvbCwgUGl0dHNi

dXJnaCwgUEEgMTUyNjAgVVNBJiN4RDtTY290dCAmYW1wOyBXaGl0ZSBIZWFsdGhjYXJlLCBUZW1w

bGUsIFRYIFVTQSYjeEQ7VGV4YXMgQSZhbXA7TSBIbHRoIFNjaSBDdHIsIENvbGwgTWVkLCBUZW1w

bGUsIFRYIFVTQSYjeEQ7SGVucnkgRm9yZCBIbHRoIFN5c3QsIERldHJvaXQsIE1JIFVTQSYjeEQ7

QmF5bG9yIENvbGwgTWVkLCBIb3VzdG9uLCBUWCA3NzAzMCBVU0E8L2F1dGgtYWRkcmVzcz48dGl0

bGVzPjx0aXRsZT5JbmZsdWVuemEgVmFjY2luZSBFZmZlY3RpdmVuZXNzIGluIHRoZSAyMDExLTIw

MTIgU2Vhc29uOiBQcm90ZWN0aW9uIEFnYWluc3QgRWFjaCBDaXJjdWxhdGluZyBWaXJ1cyBhbmQg

dGhlIEVmZmVjdCBvZiBQcmlvciBWYWNjaW5hdGlvbiBvbiBFc3RpbWF0ZXM8L3RpdGxlPjxzZWNv

bmRhcnktdGl0bGU+Q2xpbmljYWwgSW5mZWN0aW91cyBEaXNlYXNlczwvc2Vjb25kYXJ5LXRpdGxl

PjxhbHQtdGl0bGU+Q2xpbiBJbmZlY3QgRGlzPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+Q2xpbmljYWwgSW5mZWN0aW91cyBEaXNlYXNlczwvZnVsbC10aXRsZT48

L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNsaW4gSW5mZWN0IERpczwv

ZnVsbC10aXRsZT48L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4zMTktMzI3PC9wYWdlcz48dm9sdW1l

PjU4PC92b2x1bWU+PG51bWJlcj4zPC9udW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPmluZmx1ZW56

YTwva2V5d29yZD48a2V5d29yZD5tZWRpY2FsbHkgYXR0ZW5kZWQgaW5mbHVlbnphPC9rZXl3b3Jk

PjxrZXl3b3JkPnZhY2NpbmUgZWZmZWN0aXZlbmVzczwva2V5d29yZD48a2V5d29yZD5hbWJ1bGF0

b3J5IGNhcmU8L2tleXdvcmQ+PGtleXdvcmQ+aW1tdW5pemF0aW9uIHByYWN0aWNlcyBhY2lwPC9r

ZXl3b3JkPjxrZXl3b3JkPmFkdmlzb3J5LWNvbW1pdHRlZTwva2V5d29yZD48a2V5d29yZD51bml0

ZWQtc3RhdGVzPC9rZXl3b3JkPjxrZXl3b3JkPmVmZmljYWN5PC9rZXl3b3JkPjxrZXl3b3JkPnJl

Y29tbWVuZGF0aW9uczwva2V5d29yZD48a2V5d29yZD5pbW11bm9nZW5pY2l0eTwva2V5d29yZD48

a2V5d29yZD5wcmV2ZW50aW9uPC9rZXl3b3JkPjxrZXl3b3JkPmFudGlib2R5PC9rZXl3b3JkPjxr

ZXl3b3JkPmNoaWxkcmVuPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3ll

YXI+PHB1Yi1kYXRlcz48ZGF0ZT5GZWIgMTwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2Ju

PjEwNTgtNDgzODwvaXNibj48YWNjZXNzaW9uLW51bT5XT1M6MDAwMzMwNDM1OTAwMDAzPC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD4mbHQ7R28gdG8gSVNJJmd0OzovL1dP

UzowMDAzMzA0MzU5MDAwMDM8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1D

SUQ6IFBNQzQwMDcxMTE7IFBNSUQ6IDI0MjM1MjY1IDwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNv

dXJjZS1udW0+RG9pIDEwLjEwOTMvQ2lkL0NpdDczNjwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+

PGxhbmd1YWdlPkVuZ2xpc2g8L2xhbmd1YWdlPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9y

Pk9zdGVyaG9sbTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJlY051bT40NTA8L1JlY051bT48

cmVjb3JkPjxyZWMtbnVtYmVyPjQ1MDwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBw

PSJFTiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0

YW1wPSIxNDA5MzM4Mjg1Ij40NTA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0i

Sm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0

aG9yPk9zdGVyaG9sbSwgTS4gVC48L2F1dGhvcj48YXV0aG9yPktlbGxleSwgTi4gUy48L2F1dGhv

cj48YXV0aG9yPlNvbW1lciwgQS48L2F1dGhvcj48YXV0aG9yPkJlbG9uZ2lhLCBFLiBBLjwvYXV0

aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkNlbnRlciBmb3IgSW5m

ZWN0aW91cyBEaXNlYXNlIFJlc2VhcmNoIGFuZCBQb2xpY3ksIFVuaXZlcnNpdHkgb2YgTWlubmVz

b3RhLCBNTiA1NTQ1NSwgVVNBLiBtdG9AdW1uLmVkdTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRp

dGxlPkVmZmljYWN5IGFuZCBlZmZlY3RpdmVuZXNzIG9mIGluZmx1ZW56YSB2YWNjaW5lczogYSBz

eXN0ZW1hdGljIHJldmlldyBhbmQgbWV0YS1hbmFseXNpczwvdGl0bGU+PHNlY29uZGFyeS10aXRs

ZT5MYW5jZXQgSW5mZWN0IERpczwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+VGhlIExhbmNl

dC4gSW5mZWN0aW91cyBkaXNlYXNlczwvYWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxm

dWxsLXRpdGxlPkxhbmNldCBJbmZlY3QgRGlzPC9mdWxsLXRpdGxlPjxhYmJyLTE+VGhlIExhbmNl

dC4gSW5mZWN0aW91cyBkaXNlYXNlczwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+TGFuY2V0IEluZmVjdCBEaXM8L2Z1bGwtdGl0bGU+PGFiYnItMT5UaGUg

TGFuY2V0LiBJbmZlY3Rpb3VzIGRpc2Vhc2VzPC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFn

ZXM+MzYtNDQ8L3BhZ2VzPjx2b2x1bWU+MTI8L3ZvbHVtZT48bnVtYmVyPjE8L251bWJlcj48a2V5

d29yZHM+PGtleXdvcmQ+QWRvbGVzY2VudDwva2V5d29yZD48a2V5d29yZD5BZHVsdDwva2V5d29y

ZD48a2V5d29yZD5BZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPkNoaWxkPC9rZXl3b3JkPjxrZXl3b3Jk

PkNoaWxkLCBQcmVzY2hvb2w8L2tleXdvcmQ+PGtleXdvcmQ+SHVtYW5zPC9rZXl3b3JkPjxrZXl3

b3JkPkluZmx1ZW56YSBBIFZpcnVzLCBIMU4xIFN1YnR5cGUvaW1tdW5vbG9neTwva2V5d29yZD48

a2V5d29yZD5JbmZsdWVuemEgVmFjY2luZXMvKnRoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5

d29yZD5JbmZsdWVuemEsIEh1bWFuL2ltbXVub2xvZ3kvKnByZXZlbnRpb24gJmFtcDsgY29udHJv

bDwva2V5d29yZD48a2V5d29yZD5JbmZsdWVuemF2aXJ1cyBBLyppbW11bm9sb2d5PC9rZXl3b3Jk

PjxrZXl3b3JkPkluZmx1ZW56YXZpcnVzIEIvKmltbXVub2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+

TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+UGFuZGVtaWNzL3ByZXZlbnRpb24gJmFtcDsg

Y29udHJvbDwva2V5d29yZD48a2V5d29yZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFz

IFRvcGljPC9rZXl3b3JkPjxrZXl3b3JkPlNlYXNvbnM8L2tleXdvcmQ+PGtleXdvcmQ+VmFjY2lu

ZXMsIEluYWN0aXZhdGVkL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29yZD5Zb3VuZyBB

ZHVsdDwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDEyPC95ZWFyPjxwdWItZGF0

ZXM+PGRhdGU+SmFuPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTQ3NC00NDU3IChF

bGVjdHJvbmljKSYjeEQ7MTQ3My0zMDk5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4y

MjAzMjg0NDwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3

dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yMjAzMjg0NDwvdXJsPjwvcmVsYXRlZC11cmxzPjwv

dXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAxNi9TMTQ3My0zMDk5KDExKTcwMjk1

LVg8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA [3, 4] is unclear. Initially believed to be due to heat instability of the A/H1N1 construct in 2014-2015 PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Db3R0ZXI8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxS

ZWNOdW0+MTIzNzwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bNSwgNl08L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MTIzNzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0YW1w

PSIxNDU4NjUzOTY0Ij4xMjM3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv

dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv

cj5Db3R0ZXIsIEMuIFIuPC9hdXRob3I+PGF1dGhvcj5KaW4sIEguPC9hdXRob3I+PGF1dGhvcj5D

aGVuLCBaLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPk1l

ZEltbXVuZSBMTEMsIE1vdW50YWluIFZpZXcsIENhbGlmb3JuaWEsIFVuaXRlZCBTdGF0ZXMgb2Yg

QW1lcmljYS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5BIHNpbmdsZSBhbWlubyBhY2lk

IGluIHRoZSBzdGFsayByZWdpb24gb2YgdGhlIEgxTjFwZG0gaW5mbHVlbnphIHZpcnVzIEhBIHBy

b3RlaW4gYWZmZWN0cyB2aXJhbCBmdXNpb24sIHN0YWJpbGl0eSBhbmQgaW5mZWN0aXZpdHk8L3Rp

dGxlPjxzZWNvbmRhcnktdGl0bGU+UExvUyBQYXRob2c8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPlBMb1MgcGF0aG9nZW5zPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt

dGl0bGU+UExvUyBQYXRob2c8L2Z1bGwtdGl0bGU+PGFiYnItMT5QTG9TIHBhdGhvZ2VuczwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+UExvUyBQYXRob2c8

L2Z1bGwtdGl0bGU+PGFiYnItMT5QTG9TIHBhdGhvZ2VuczwvYWJici0xPjwvYWx0LXBlcmlvZGlj

YWw+PHBhZ2VzPmUxMDAzODMxPC9wYWdlcz48dm9sdW1lPjEwPC92b2x1bWU+PG51bWJlcj4xPC9u

dW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFtaW5vIEFjaWQgU3Vic3RpdHV0aW9uPC9rZXl3b3Jk

PjxrZXl3b3JkPkFuaW1hbHM8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBNZW1icmFuZTwva2V5d29y

ZD48a2V5d29yZD5DaGljayBFbWJyeW88L2tleXdvcmQ+PGtleXdvcmQ+RG9nczwva2V5d29yZD48

a2V5d29yZD5GZXJyZXRzPC9rZXl3b3JkPjxrZXl3b3JkPkhlbWFnZ2x1dGluaW4gR2x5Y29wcm90

ZWlucywgSW5mbHVlbnphIFZpcnVzL2dlbmV0aWNzLyptZXRhYm9saXNtPC9rZXl3b3JkPjxrZXl3

b3JkPkhvdCBUZW1wZXJhdHVyZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtl

eXdvcmQ+SHlkcm9nZW4tSW9uIENvbmNlbnRyYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SW5mbHVl

bnphIEEgVmlydXMsIEgxTjEgU3VidHlwZS8qcGF0aG9nZW5pY2l0eS8qcGh5c2lvbG9neTwva2V5

d29yZD48a2V5d29yZD5JbmZsdWVuemEgVmFjY2luZXMvZ2VuZXRpY3MvbWV0YWJvbGlzbTwva2V5

d29yZD48a2V5d29yZD5NYWRpbiBEYXJieSBDYW5pbmUgS2lkbmV5IENlbGxzPC9rZXl3b3JkPjxr

ZXl3b3JkPk11dGF0aW9uLCBNaXNzZW5zZTwva2V5d29yZD48a2V5d29yZD5PcnRob215eG92aXJp

ZGFlIEluZmVjdGlvbnMvZ2VuZXRpY3MvKm1ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+UHJv

dGVpbiBTdHJ1Y3R1cmUsIFRlcnRpYXJ5PC9rZXl3b3JkPjxrZXl3b3JkPipWaXJ1cyBJbnRlcm5h

bGl6YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+VmlydXMgUmVwbGljYXRpb24vKnBoeXNpb2xvZ3k8

L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48cHViLWRhdGVzPjxk

YXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1NTMtNzM3NCAoRWxlY3Ry

b25pYykmI3hEOzE1NTMtNzM2NiAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjQzOTE0

OTg8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNi

aS5ubG0ubmloLmdvdi9wdWJtZWQvMjQzOTE0OTg8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGN1c3RvbTI+Mzg3OTM2MzwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTM3

MS9qb3VybmFsLnBwYXQuMTAwMzgzMTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+

PC9DaXRlPjxDaXRlPjxBdXRob3I+TyZhcG9zO0Rvbm5lbGw8L0F1dGhvcj48WWVhcj4yMDE0PC9Z

ZWFyPjxSZWNOdW0+MTIzODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTIzODwvcmVjLW51

bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZl

cjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0YW1wPSIxNDU4NjUzOTgwIj4xMjM4PC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBl

Pjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5PJmFwb3M7RG9ubmVsbCwgQy4gRC48L2F1

dGhvcj48YXV0aG9yPlZvZ2VsLCBMLjwvYXV0aG9yPjxhdXRob3I+TWF0c3Vva2EsIFkuPC9hdXRo

b3I+PGF1dGhvcj5KaW4sIEguPC9hdXRob3I+PGF1dGhvcj5TdWJiYXJhbywgSy48L2F1dGhvcj48

L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5MYWJvcmF0b3J5IG9mIEluZmVj

dGlvdXMgRGlzZWFzZXMsIE5JQUlELCBOSUgsIEJldGhlc2RhLCBNYXJ5bGFuZCwgVVNBLiYjeEQ7

TWVkSW1tdW5lIExMQywgTW91bnRhaW4gVmlldywgQ2FsaWZvcm5pYSwgVVNBLiYjeEQ7TGFib3Jh

dG9yeSBvZiBJbmZlY3Rpb3VzIERpc2Vhc2VzLCBOSUFJRCwgTklILCBCZXRoZXNkYSwgTWFyeWxh

bmQsIFVTQSBrc3ViYmFyYW9AbmlhaWQubmloLmdvdi48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0

aXRsZT5UaGUgbWF0cml4IGdlbmUgc2VnbWVudCBkZXN0YWJpbGl6ZXMgdGhlIGFjaWQgYW5kIHRo

ZXJtYWwgc3RhYmlsaXR5IG9mIHRoZSBoZW1hZ2dsdXRpbmluIG9mIHBhbmRlbWljIGxpdmUgYXR0

ZW51YXRlZCBpbmZsdWVuemEgdmlydXMgdmFjY2luZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

SiBWaXJvbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+Sm91cm5hbCBvZiB2aXJvbG9neTwv

YWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogVmlyb2w8L2Z1bGwt

dGl0bGU+PGFiYnItMT5Kb3VybmFsIG9mIHZpcm9sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxh

bHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIFZpcm9sPC9mdWxsLXRpdGxlPjxhYmJyLTE+Sm91

cm5hbCBvZiB2aXJvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEyMzc0LTg0

PC9wYWdlcz48dm9sdW1lPjg4PC92b2x1bWU+PG51bWJlcj4yMTwvbnVtYmVyPjxrZXl3b3Jkcz48

a2V5d29yZD5EcnVnIFN0YWJpbGl0eTwva2V5d29yZD48a2V5d29yZD5IZW1hZ2dsdXRpbmlucy8q

Y2hlbWlzdHJ5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5IeWRy

b2dlbi1Jb24gQ29uY2VudHJhdGlvbjwva2V5d29yZD48a2V5d29yZD5JbmZsdWVuemEgQSBWaXJ1

cywgSDFOMSBTdWJ0eXBlLypjaGVtaXN0cnkvZ2VuZXRpY3MvKnBoeXNpb2xvZ3k8L2tleXdvcmQ+

PGtleXdvcmQ+SW5mbHVlbnphIFZhY2NpbmVzLypjaGVtaXN0cnkvZ2VuZXRpY3M8L2tleXdvcmQ+

PGtleXdvcmQ+UHJvdGVpbiBTdGFiaWxpdHkvZHJ1ZyBlZmZlY3RzL3JhZGlhdGlvbiBlZmZlY3Rz

PC9rZXl3b3JkPjxrZXl3b3JkPlJlYXNzb3J0YW50IFZpcnVzZXMvY2hlbWlzdHJ5L2dlbmV0aWNz

L3BoeXNpb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VGVtcGVyYXR1cmU8L2tleXdvcmQ+PGtleXdv

cmQ+VmFjY2luZXMsIEF0dGVudWF0ZWQvY2hlbWlzdHJ5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3

b3JkPlZpcmFsIE1hdHJpeCBQcm90ZWlucy8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Vmly

dXMgUmVwbGljYXRpb24vZHJ1ZyBlZmZlY3RzL3JhZGlhdGlvbiBlZmZlY3RzPC9rZXl3b3JkPjwv

a2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5Ob3Y8L2Rh

dGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xMDk4LTU1MTQgKEVsZWN0cm9uaWMpJiN4RDsw

MDIyLTUzOFggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1MTIyNzg5PC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzI1MTIyNzg5PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPjQy

NDg4OTY8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjExMjgvSlZJLjAxMTA3

LTE0PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Db3R0ZXI8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxS

ZWNOdW0+MTIzNzwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bNSwgNl08L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MTIzNzwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0YW1w

PSIxNDU4NjUzOTY0Ij4xMjM3PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv

dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv

cj5Db3R0ZXIsIEMuIFIuPC9hdXRob3I+PGF1dGhvcj5KaW4sIEguPC9hdXRob3I+PGF1dGhvcj5D

aGVuLCBaLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPk1l

ZEltbXVuZSBMTEMsIE1vdW50YWluIFZpZXcsIENhbGlmb3JuaWEsIFVuaXRlZCBTdGF0ZXMgb2Yg

QW1lcmljYS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5BIHNpbmdsZSBhbWlubyBhY2lk

IGluIHRoZSBzdGFsayByZWdpb24gb2YgdGhlIEgxTjFwZG0gaW5mbHVlbnphIHZpcnVzIEhBIHBy

b3RlaW4gYWZmZWN0cyB2aXJhbCBmdXNpb24sIHN0YWJpbGl0eSBhbmQgaW5mZWN0aXZpdHk8L3Rp

dGxlPjxzZWNvbmRhcnktdGl0bGU+UExvUyBQYXRob2c8L3NlY29uZGFyeS10aXRsZT48YWx0LXRp

dGxlPlBMb1MgcGF0aG9nZW5zPC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwt

dGl0bGU+UExvUyBQYXRob2c8L2Z1bGwtdGl0bGU+PGFiYnItMT5QTG9TIHBhdGhvZ2VuczwvYWJi

ci0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+UExvUyBQYXRob2c8

L2Z1bGwtdGl0bGU+PGFiYnItMT5QTG9TIHBhdGhvZ2VuczwvYWJici0xPjwvYWx0LXBlcmlvZGlj

YWw+PHBhZ2VzPmUxMDAzODMxPC9wYWdlcz48dm9sdW1lPjEwPC92b2x1bWU+PG51bWJlcj4xPC9u

dW1iZXI+PGtleXdvcmRzPjxrZXl3b3JkPkFtaW5vIEFjaWQgU3Vic3RpdHV0aW9uPC9rZXl3b3Jk

PjxrZXl3b3JkPkFuaW1hbHM8L2tleXdvcmQ+PGtleXdvcmQ+Q2VsbCBNZW1icmFuZTwva2V5d29y

ZD48a2V5d29yZD5DaGljayBFbWJyeW88L2tleXdvcmQ+PGtleXdvcmQ+RG9nczwva2V5d29yZD48

a2V5d29yZD5GZXJyZXRzPC9rZXl3b3JkPjxrZXl3b3JkPkhlbWFnZ2x1dGluaW4gR2x5Y29wcm90

ZWlucywgSW5mbHVlbnphIFZpcnVzL2dlbmV0aWNzLyptZXRhYm9saXNtPC9rZXl3b3JkPjxrZXl3

b3JkPkhvdCBUZW1wZXJhdHVyZTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtl

eXdvcmQ+SHlkcm9nZW4tSW9uIENvbmNlbnRyYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SW5mbHVl

bnphIEEgVmlydXMsIEgxTjEgU3VidHlwZS8qcGF0aG9nZW5pY2l0eS8qcGh5c2lvbG9neTwva2V5

d29yZD48a2V5d29yZD5JbmZsdWVuemEgVmFjY2luZXMvZ2VuZXRpY3MvbWV0YWJvbGlzbTwva2V5

d29yZD48a2V5d29yZD5NYWRpbiBEYXJieSBDYW5pbmUgS2lkbmV5IENlbGxzPC9rZXl3b3JkPjxr

ZXl3b3JkPk11dGF0aW9uLCBNaXNzZW5zZTwva2V5d29yZD48a2V5d29yZD5PcnRob215eG92aXJp

ZGFlIEluZmVjdGlvbnMvZ2VuZXRpY3MvKm1ldGFib2xpc208L2tleXdvcmQ+PGtleXdvcmQ+UHJv

dGVpbiBTdHJ1Y3R1cmUsIFRlcnRpYXJ5PC9rZXl3b3JkPjxrZXl3b3JkPipWaXJ1cyBJbnRlcm5h

bGl6YXRpb248L2tleXdvcmQ+PGtleXdvcmQ+VmlydXMgUmVwbGljYXRpb24vKnBoeXNpb2xvZ3k8

L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48cHViLWRhdGVzPjxk

YXRlPkphbjwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVzPjxpc2JuPjE1NTMtNzM3NCAoRWxlY3Ry

b25pYykmI3hEOzE1NTMtNzM2NiAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjQzOTE0

OTg8L2FjY2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHA6Ly93d3cubmNi

aS5ubG0ubmloLmdvdi9wdWJtZWQvMjQzOTE0OTg8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+

PGN1c3RvbTI+Mzg3OTM2MzwvY3VzdG9tMj48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTM3

MS9qb3VybmFsLnBwYXQuMTAwMzgzMTwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+

PC9DaXRlPjxDaXRlPjxBdXRob3I+TyZhcG9zO0Rvbm5lbGw8L0F1dGhvcj48WWVhcj4yMDE0PC9Z

ZWFyPjxSZWNOdW0+MTIzODwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTIzODwvcmVjLW51

bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZl

cjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0YW1wPSIxNDU4NjUzOTgwIj4xMjM4PC9rZXk+PC9m

b3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBl

Pjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5PJmFwb3M7RG9ubmVsbCwgQy4gRC48L2F1

dGhvcj48YXV0aG9yPlZvZ2VsLCBMLjwvYXV0aG9yPjxhdXRob3I+TWF0c3Vva2EsIFkuPC9hdXRo

b3I+PGF1dGhvcj5KaW4sIEguPC9hdXRob3I+PGF1dGhvcj5TdWJiYXJhbywgSy48L2F1dGhvcj48

L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5MYWJvcmF0b3J5IG9mIEluZmVj

dGlvdXMgRGlzZWFzZXMsIE5JQUlELCBOSUgsIEJldGhlc2RhLCBNYXJ5bGFuZCwgVVNBLiYjeEQ7

TWVkSW1tdW5lIExMQywgTW91bnRhaW4gVmlldywgQ2FsaWZvcm5pYSwgVVNBLiYjeEQ7TGFib3Jh

dG9yeSBvZiBJbmZlY3Rpb3VzIERpc2Vhc2VzLCBOSUFJRCwgTklILCBCZXRoZXNkYSwgTWFyeWxh

bmQsIFVTQSBrc3ViYmFyYW9AbmlhaWQubmloLmdvdi48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0

aXRsZT5UaGUgbWF0cml4IGdlbmUgc2VnbWVudCBkZXN0YWJpbGl6ZXMgdGhlIGFjaWQgYW5kIHRo

ZXJtYWwgc3RhYmlsaXR5IG9mIHRoZSBoZW1hZ2dsdXRpbmluIG9mIHBhbmRlbWljIGxpdmUgYXR0

ZW51YXRlZCBpbmZsdWVuemEgdmlydXMgdmFjY2luZXM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

SiBWaXJvbDwvc2Vjb25kYXJ5LXRpdGxlPjxhbHQtdGl0bGU+Sm91cm5hbCBvZiB2aXJvbG9neTwv

YWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogVmlyb2w8L2Z1bGwt

dGl0bGU+PGFiYnItMT5Kb3VybmFsIG9mIHZpcm9sb2d5PC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxh

bHQtcGVyaW9kaWNhbD48ZnVsbC10aXRsZT5KIFZpcm9sPC9mdWxsLXRpdGxlPjxhYmJyLTE+Sm91

cm5hbCBvZiB2aXJvbG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEyMzc0LTg0

PC9wYWdlcz48dm9sdW1lPjg4PC92b2x1bWU+PG51bWJlcj4yMTwvbnVtYmVyPjxrZXl3b3Jkcz48

a2V5d29yZD5EcnVnIFN0YWJpbGl0eTwva2V5d29yZD48a2V5d29yZD5IZW1hZ2dsdXRpbmlucy8q

Y2hlbWlzdHJ5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5IeWRy

b2dlbi1Jb24gQ29uY2VudHJhdGlvbjwva2V5d29yZD48a2V5d29yZD5JbmZsdWVuemEgQSBWaXJ1

cywgSDFOMSBTdWJ0eXBlLypjaGVtaXN0cnkvZ2VuZXRpY3MvKnBoeXNpb2xvZ3k8L2tleXdvcmQ+

PGtleXdvcmQ+SW5mbHVlbnphIFZhY2NpbmVzLypjaGVtaXN0cnkvZ2VuZXRpY3M8L2tleXdvcmQ+

PGtleXdvcmQ+UHJvdGVpbiBTdGFiaWxpdHkvZHJ1ZyBlZmZlY3RzL3JhZGlhdGlvbiBlZmZlY3Rz

PC9rZXl3b3JkPjxrZXl3b3JkPlJlYXNzb3J0YW50IFZpcnVzZXMvY2hlbWlzdHJ5L2dlbmV0aWNz

L3BoeXNpb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+VGVtcGVyYXR1cmU8L2tleXdvcmQ+PGtleXdv

cmQ+VmFjY2luZXMsIEF0dGVudWF0ZWQvY2hlbWlzdHJ5L2dlbmV0aWNzPC9rZXl3b3JkPjxrZXl3

b3JkPlZpcmFsIE1hdHJpeCBQcm90ZWlucy8qZ2VuZXRpY3M8L2tleXdvcmQ+PGtleXdvcmQ+Vmly

dXMgUmVwbGljYXRpb24vZHJ1ZyBlZmZlY3RzL3JhZGlhdGlvbiBlZmZlY3RzPC9rZXl3b3JkPjwv

a2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTQ8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5Ob3Y8L2Rh

dGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xMDk4LTU1MTQgKEVsZWN0cm9uaWMpJiN4RDsw

MDIyLTUzOFggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjI1MTIyNzg5PC9hY2Nlc3Np

b24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5n

b3YvcHVibWVkLzI1MTIyNzg5PC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxjdXN0b20yPjQy

NDg4OTY8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjExMjgvSlZJLjAxMTA3

LTE0PC9lbGVjdHJvbmljLXJlc291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA [5, 6], manufacturer’s modifications of the vaccine did not improve VE in 2015-2016 season ADDIN EN.CITE <EndNote><Cite><Author>Jackson ML</Author><Year>2017</Year><RecNum>25</RecNum><DisplayText>[7]</DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181071">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Jackson ML, </author><author>Chung JR, </author><author>Jackson LA, </author><author>Phillips CH, </author><author>Benoit J, </author><author>Monto AS, </author><author>Martin ET, </author><author>Belongia EA, </author><author>McLean HQ, </author><author>Gaglani M, </author><author>Murthy K, </author><author>Zimmerman RK, </author><author>Nowalk MP, </author><author>Fry AM, </author><author>Flannery B</author></authors></contributors><titles><title>Influenza Vaccine Effectiveness in the United States — 2015/16 Season</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><volume>In Press</volume><dates><year>2017</year></dates><urls></urls></record></Cite></EndNote>[7]. In response to this low VE, the Advisory Committee on Immunization Practices does not currently support the use of LAIV, thereby removing the intranasal delivery mechanism preferred by many children. Studies are needed to help to determine what accounts for the differences in VE between LAIV and inactivated influenza vaccine (IIV). In a previous study of children ages 3 to 17 years, post 2014-2015 influenza vaccination antibody titers were significantly higher in response to IIV than to LAIV ADDIN EN.CITE <EndNote><Cite><Author>Levine</Author><Year>2016</Year><RecNum>28</RecNum><DisplayText>[8]</DisplayText><record><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181994">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levine, Min Z</author><author>Martin, Judith M</author><author>Gross, F Liaini</author><author>Jefferson, Stacie</author><author>Cole, Kelly Stefano</author><author>Archibald, Crystal Ann</author><author>Nowalk, Mary Patricia</author><author>Susick, Michael</author><author>Moehling, Krissy</author><author>Spencer, Sarah</author></authors></contributors><titles><title>Neutralizing Antibody Responses to Antigenically Drifted Influenza A (H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination</title><secondary-title>Clinical and Vaccine Immunology</secondary-title></titles><periodical><full-title>Clinical and Vaccine Immunology</full-title></periodical><pages>831-839</pages><volume>23</volume><number>10</number><dates><year>2016</year></dates><isbn>1556-6811</isbn><urls></urls></record></Cite></EndNote>[8]. Moreover, microneutralization antibodies measuring cross-reactive protection against influenza were significantly higher among recipients of IIV than LAIV. It is likely that other immune responses, including cellular or mucosal immune responses, differ between LAIV and IIV recipients. RNA sequencing is a technique that has been used to examine the cellular transcriptome such as gene expression, and provides a snapshot at the time of blood collection. Changes in the transcriptome before and after vaccination may identify transcription profiles and pathways of response that can be used for future vaccine development. This study was designed to compare the RNA seq responses to the 2015-2016 IIV versus LAIV in children during the last year when LAIV use was recommended in the U.S. Specifically, selected gene profiles known to be related to viral infection, as well as the innate and adaptive immune responses to influenza, were compared. METHODSThis study was approved by the University of Pittsburgh Institutional Review Board. Written informed consent was obtained from the participants’ parents.Subjects, Eligibility and EnrollmentThis study was conducted before influenza was circulating in the region ADDIN EN.CITE <EndNote><Cite><Author>Russell</Author><Year>2016</Year><RecNum>1522</RecNum><DisplayText>[9]</DisplayText><record><rec-number>1522</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1487972701">1522</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Russell, Kate</author></authors></contributors><titles><title>Update: Influenza Activity—United States, October 4, 2015–February 6, 2016</title><secondary-title>MMWR. Morbidity and mortality weekly report</secondary-title></titles><periodical><full-title>MMWR Morb Mortal Wkly Rep</full-title><abbr-1>MMWR. Morbidity and mortality weekly report</abbr-1></periodical><volume>65</volume><dates><year>2016</year></dates><urls></urls></record></Cite></EndNote>[9]. From September through December 2015, a convenience sample of healthy children aged 3 through 17 years who planned to receive influenza vaccine were recruited from 3 primary care offices in the Pittsburgh area. Exclusion criteria included body weight <17 kilograms, having an immunosuppressive disease, taking immunosuppressive medicine or high dose oral steroids, pregnancy, and having a severe allergy to the influenza vaccine or its components. Parents could choose which form of the quadrivalent vaccine they preferred and the children were grouped by the vaccine received. All children received quadrivalent vaccines: IIV was either Fluzone (Sanofi Pasteur) or Fluarix (GlaxoSmithKline) as determined by their health insurance. Quadrivalent LAIV was FluMist (MedImmune). Demographic data were provided by the families and/or extracted from the electronic medical record. Specimen Collection and ProcessingOn Day 0, participants provided blood samples prior to receiving influenza vaccine as part of their clinical care; they returned on Day 7 (range 6-10 days) for an additional blood draw. Within 4-6 hours of collection, blood samples collected into PAXgene tubes (Becton Dickinson) were centrifuged at 3200 rpm for 10-15 minutes and stored at -70°Celcius until further analysis. RNA sequencingTotal RNA was isolated from PAXgene tubes using the PAXgene Blood RNA Kit following the manufacturer’s protocol. The 89 transcripts selected for testing were based on the knowledge of the investigators and local experts of genes known to have a role in influenza and other viral infections and a review of the medical literature for prior similar studies (See Supplemental Tables for a list of all transcripts). Both LAIV and IIV recipients were tested for all 89 transcripts. RNA quality and quantity were assessed by Agilent Tapestation 2200 and Invitrogen Qubit 2.0 fluorometer. Using 50 ng of total RNA, a multiplexed gene expression profiling panel of the selected targets was performed using the TruSeq Targeted RNA Expression Reference Guide, Rev. C ADDIN EN.CITE <EndNote><Cite><Author>Illumina</Author><Year>2016</Year><RecNum>1531</RecNum><DisplayText>[10]</DisplayText><record><rec-number>1531</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1488406469">1531</key></foreign-keys><ref-type name="Generic">13</ref-type><contributors><authors><author>Illumina</author></authors></contributors><titles><title>TruSeq Targeted RNA Expression Reference Guide Revision C</title></titles><dates><year>2016</year><pub-dates><date>2016</date></pub-dates></dates><pub-location>San Diego CA</pub-location><urls></urls></record></Cite></EndNote>[10]. Single-read 50 base pairs (bp) sequencing was performed on an Illumina NextSeq 500 with an average of 2 million reads per sample. Sequencing libraries were normalized to 2nM and then pooled. AlignmentThe banded Smith-Waterman algorithm was used to align clusters from each sample against the amplicon sequences provided in the kits to determine similar regions between 2 sequences, comparing segments of all possible lengths. If the start of a read matched a probe sequence with no more than 1 mismatch, the full length of the read was aligned against the amplicon target for that sequence. Alignments that included more than 3 indels (insertions or deletions) were excluded from alignment results. Statistical AnalysesDepth of sequencing, variance estimation and calculation of p and q values. Depth of sequencing was used to compare samples for differences between Day 0 and Day 7. For each RNA transcript, the raw counts and the geometric mean of aligned read counts were calculated for all samples. A scaling factor (median of the ratio of raw counts to the geometric mean) was then used to normalize raw counts, dividing raw counts by the scaling factor to enable comparison of non-differentially expressed transcripts. The bias inherent in estimating variance is correlated with the number of biological replicates; thus, variance was calculated using data from all sample IDs rather than calculating for each sample name separately. The squared coefficient of variation was calculated by dividing the raw variance by the square of the mean. Fold differences in normalized RNA seq counts from Day 0 to Day 7 were calculated and log2 transformed. A negative binomial distribution was used to model the normalized transcript abundance to derive a P-value for the differential expression (up- or down-regulations) of each transcript. Q-values were computed using the Benjamini-Hochberg procedure to control the false discovery rate by correcting for multiple hypothesis testing.Patient characteristics. Demographic characteristics of recipients, including age groups (3-8 years vs. 9-17 years), sex, race (Black vs. non-Black), health insurance (public vs. private insurance), parent’s educational level (high school or less vs. some college or higher degree), and household smoking status, were compared by vaccine type (LAIV vs. IIV) using Chi-square or Fisher’s exact tests. Statistical significance was set at P < 0.05.RESULTSSeventy-two participants provided adequate Day 0 and Day 7 blood samples for analysis. The demographic characteristics of IIV recipients did not differ from LAIV recipients (Table 1). Differentially expressed genes (DEGs) with a p-value?<?0.05 were identified and are shown in Table 2. Following IIV vaccination, 7 genes demonstrated significant differential expression at Day 7, all down-regulated; whereas, LAIV vaccination resulted in a total of 8 genes with significant differential expression at Day 7, with 5 up-regulated and 3 down-regulated. Two genes with significant differential expression at Day 7 were common to both vaccine types, both were down-regulated (CCL 7 and CXCR4). Most interesting was the striking difference between the two vaccines, where IIV vaccination resulted in down-regulated 7 genes compared to LAIV vaccination which resulted primarily in up-regulation of 5 different genes. Figure 1, a heat map of the gene expression, shows the differences between RNA seq responses to the two vaccine types. DiscussionSystems biology approaches have been used in influenza research since 2011. The present study was designed to analyze RNA transcripts following IIV compared to LAIV vaccination during a year when the influenza vaccine was well-matched to the circulating strains. Our results demonstrated a remarkable difference between the two vaccines, where most of the genes expressed following IIV vaccination were down-regulated, while genes expressed after LAIV vaccination were predominantly upregulated. In addition, we found a greater number of significant transcriptional changes with IIV than LAIV, as has been found by others ADDIN EN.CITE <EndNote><Cite><Author>Cao</Author><Year>2014</Year><RecNum>1536</RecNum><DisplayText>[11]</DisplayText><record><rec-number>1536</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1488572425">1536</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Cao, Raquel G</author><author>Suarez, Nicolas M</author><author>Obermoser, Gerlinde</author><author>Lopez, Santiago MC</author><author>Flano, Emilio</author><author>Mertz, Sara E</author><author>Albrecht, Randy A</author><author>García-Sastre, Adolfo</author><author>Mejias, Asuncion</author><author>Xu, Hui</author></authors></contributors><titles><title>Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children</title><secondary-title>Journal of Infectious Diseases</secondary-title></titles><periodical><full-title>Journal of Infectious Diseases</full-title></periodical><pages>224-233</pages><volume>210</volume><number>2</number><dates><year>2014</year></dates><isbn>0022-1899</isbn><urls></urls></record></Cite></EndNote>[11]. The expression of two genes, CCL7 and CXCR4, demonstrated similar changes in magnitude and direction in both IIV and LAIV recipients. The genes with significant differential expression in response to IIV included the T cell related cytokine interleukin (IL)4, which is a B cell stimulating cytokine produced by activated Type 2 T-helper cells (Th2) and IL12B (IL12p40) a cytokine subunit of IL12 and IL23, which prime Th1 and Th17 responses, respectively. This finding suggests decreased T cell activation 7 days post-vaccination. Interferon alpha 1 (IFN A1), a canonical antiviral gene was also downregulated by vaccination. Finally, monocyte and neutrophil chemokines and receptors were decreased, including CCL2 (MCP-1), CCL7 (MCP-3), and CXCR4 (SDF1 receptor), which mediate monocyte chemotaxis, and IL8, a prominent neutrophil chemoattractant. These data suggest an anti-inflammatory state 7 days post-vaccination. Unlike the PBMC response to IIV, we found five upregulated DEGs following LAIV that indicates an interferon stimulated gene (ISG) response.??This ISG response to LAIV was distinct from that observed with IIV. Among these five genes, two are involved in inducing or regulating apoptosis of infected or abnormal cells:??Interferon alpha Inducible Protein 6 (IFI6) and Tumor Necrosis Factor Superfamily member 10 (TFNSF10/TRAIL).??Another two upregulated DEGs, Myxovirus Dynamin Like GTPase 1 (MX1) and Interferon Induced Protein with Tetratricopeptide Repeats 3 (IFIT3), are known inhibitors of influenza virus replication and promote interferon signaling. ?Finally, C-X-C Motif Chemokine Ligand 10 (CXCL10/IP-10) is a type II interferon induced gene that promotes lymphocyte chemotaxis.? These upregulated DEGs are largely involved in the canonical interferon signaling pathway that is invoked in response to live virus infection. Why LAIV induces interferon signaling, while IIV did not at this time point, is unknown, but intriguing. The association of LAIV vaccination with upregulation of genes involved in apoptosis may be indications of alternate mechanisms of action ADDIN EN.CITE <EndNote><Cite><Author>Dou</Author><Year>2015</Year><RecNum>1529</RecNum><DisplayText>[12]</DisplayText><record><rec-number>1529</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1488225381">1529</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Dou, Yaling</author><author>Fu, Binqing</author><author>Sun, Rui</author><author>Li, Wenting</author><author>Hu, Wanfu</author><author>Tian, Zhigang</author><author>Wei, Haiming</author></authors></contributors><titles><title>Influenza vaccine induces intracellular immune memory of human NK cells</title><secondary-title>PloS one</secondary-title></titles><periodical><full-title>PLoS One</full-title><abbr-1>PloS one</abbr-1></periodical><pages>e0121258</pages><volume>10</volume><number>3</number><dates><year>2015</year></dates><isbn>1932-6203</isbn><urls></urls></record></Cite></EndNote>[12], and warrant further evaluation of immune responses associated with LAIV vaccination. The dramatic difference between transcriptomic responses to the two vaccines and previous findings that children who received LAIV generated a less robust IgG antibody response than those who received IIV ADDIN EN.CITE <EndNote><Cite><Author>Levine</Author><Year>2016</Year><RecNum>28</RecNum><DisplayText>[8]</DisplayText><record><rec-number>28</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181994">28</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Levine, Min Z</author><author>Martin, Judith M</author><author>Gross, F Liaini</author><author>Jefferson, Stacie</author><author>Cole, Kelly Stefano</author><author>Archibald, Crystal Ann</author><author>Nowalk, Mary Patricia</author><author>Susick, Michael</author><author>Moehling, Krissy</author><author>Spencer, Sarah</author></authors></contributors><titles><title>Neutralizing Antibody Responses to Antigenically Drifted Influenza A (H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination</title><secondary-title>Clinical and Vaccine Immunology</secondary-title></titles><periodical><full-title>Clinical and Vaccine Immunology</full-title></periodical><pages>831-839</pages><volume>23</volume><number>10</number><dates><year>2016</year></dates><isbn>1556-6811</isbn><urls></urls></record></Cite></EndNote>[8] provide new insights to help explain the lower vaccine effectiveness of LAIV observed during the 2015-16 influenza season ADDIN EN.CITE <EndNote><Cite><Author>Jackson ML</Author><Year>2017</Year><RecNum>25</RecNum><DisplayText>[7]</DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181071">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Jackson ML, </author><author>Chung JR, </author><author>Jackson LA, </author><author>Phillips CH, </author><author>Benoit J, </author><author>Monto AS, </author><author>Martin ET, </author><author>Belongia EA, </author><author>McLean HQ, </author><author>Gaglani M, </author><author>Murthy K, </author><author>Zimmerman RK, </author><author>Nowalk MP, </author><author>Fry AM, </author><author>Flannery B</author></authors></contributors><titles><title>Influenza Vaccine Effectiveness in the United States — 2015/16 Season</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><volume>In Press</volume><dates><year>2017</year></dates><urls></urls></record></Cite></EndNote>[7]. Cao et al., found differential expression in the IIV group of plasma cell-mediated and inflammation genes, but in the LAIV group found IFN and cell-cycle-related transcripts ADDIN EN.CITE <EndNote><Cite><Author>Cao</Author><Year>2014</Year><RecNum>1536</RecNum><DisplayText>[11]</DisplayText><record><rec-number>1536</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1488572425">1536</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Cao, Raquel G</author><author>Suarez, Nicolas M</author><author>Obermoser, Gerlinde</author><author>Lopez, Santiago MC</author><author>Flano, Emilio</author><author>Mertz, Sara E</author><author>Albrecht, Randy A</author><author>García-Sastre, Adolfo</author><author>Mejias, Asuncion</author><author>Xu, Hui</author></authors></contributors><titles><title>Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children</title><secondary-title>Journal of Infectious Diseases</secondary-title></titles><periodical><full-title>Journal of Infectious Diseases</full-title></periodical><pages>224-233</pages><volume>210</volume><number>2</number><dates><year>2014</year></dates><isbn>0022-1899</isbn><urls></urls></record></Cite></EndNote>[11]. IIV has been found to induce expression of IFN genes at day 1 post vaccination, while LAIV was not found to be associated with these changes until day 7 [10]. It is possible that IIV induced gene expression occurs earlier than LAIV and this temporal difference in transcriptional regulation may affect protective immunity. The pattern of overexpression of IFN genes has been suggested as a biomarker of vaccination response ADDIN EN.CITE <EndNote><Cite><Author>Zhu</Author><Year>2010</Year><RecNum>1822</RecNum><DisplayText>[13]</DisplayText><record><rec-number>1822</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1498237764">1822</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Zhu, Wei</author><author>Higgs, Brandon W</author><author>Morehouse, Chris</author><author>Streicher, Katie</author><author>Ambrose, Christopher S</author><author>Woo, Jennifer</author><author>Kemble, George W</author><author>Jallal, Bahija</author><author>Yao, Yihong</author></authors></contributors><titles><title>A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children</title><secondary-title>Vaccine</secondary-title></titles><periodical><full-title>Vaccine</full-title><abbr-1>Vaccine</abbr-1></periodical><pages>2865-2876</pages><volume>28</volume><number>16</number><dates><year>2010</year></dates><isbn>0264-410X</isbn><urls></urls></record></Cite></EndNote>[13]. Certain IFN-related DEGs were also correlated with antibody response. We add to this important work of Cao et al., by including a larger sample size of children using data from the last season that LAIV was widely used and a season when LAIV did not perform well, as reported by the US Flu VE Network ADDIN EN.CITE <EndNote><Cite><Author>Jackson ML</Author><Year>2017</Year><RecNum>25</RecNum><DisplayText>[7]</DisplayText><record><rec-number>25</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501181071">25</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Jackson ML, </author><author>Chung JR, </author><author>Jackson LA, </author><author>Phillips CH, </author><author>Benoit J, </author><author>Monto AS, </author><author>Martin ET, </author><author>Belongia EA, </author><author>McLean HQ, </author><author>Gaglani M, </author><author>Murthy K, </author><author>Zimmerman RK, </author><author>Nowalk MP, </author><author>Fry AM, </author><author>Flannery B</author></authors></contributors><titles><title>Influenza Vaccine Effectiveness in the United States — 2015/16 Season</title><secondary-title>New England Journal of Medicine</secondary-title></titles><periodical><full-title>New England Journal of Medicine</full-title></periodical><volume>In Press</volume><dates><year>2017</year></dates><urls></urls></record></Cite></EndNote>[7].Identification of predictive signatures of serologic response to vaccination is an emerging field of systems biology. Bucasas et al. were among the first to demonstrate a positive correlation between HA titers and upregulation of interferon-responsive genes early after IIV vaccination ADDIN EN.CITE <EndNote><Cite><Author>Bucasas</Author><Year>2011</Year><RecNum>1509</RecNum><DisplayText>[14]</DisplayText><record><rec-number>1509</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1487708030">1509</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bucasas, Kristine L</author><author>Franco, Luis M</author><author>Shaw, Chad A</author><author>Bray, Molly S</author><author>Wells, Janet M</author><author>Ni?o, Diane</author><author>Arden, Nancy</author><author>Quarles, John M</author><author>Couch, Robert B</author><author>Belmont, John W</author></authors></contributors><titles><title>Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans</title><secondary-title>Journal of Infectious Diseases</secondary-title></titles><periodical><full-title>Journal of Infectious Diseases</full-title></periodical><pages>921-929</pages><volume>203</volume><number>7</number><dates><year>2011</year></dates><isbn>0022-1899</isbn><urls></urls><custom2>PMC3068032</custom2></record></Cite></EndNote>[14]. Elevated antibody titers to IIV are correlated with upregulation of B-cell specific transcripts, upregulation of immunoglobulin genes, and proliferation-associated genes. These responses may be predictors of vaccine-specific antibody and plasmablast responses at seven days post vaccination ADDIN EN.CITE <EndNote><Cite><Author>Tan</Author><Year>2014</Year><RecNum>1516</RecNum><DisplayText>[15]</DisplayText><record><rec-number>1516</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1487712884">1516</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Tan, Y.</author><author>Tamayo, P.</author><author>Nakaya, H.</author><author>Pulendran, B.</author><author>Mesirov, J.P. </author><author>Haining, W.N.</author></authors></contributors><titles><title>Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response</title><secondary-title>European Journal of Immunology</secondary-title></titles><periodical><full-title>European Journal of Immunology</full-title></periodical><pages>285-295</pages><volume>44</volume><number>1</number><dates><year>2014</year></dates><urls></urls><electronic-resource-num>10.1002/eji.201343657</electronic-resource-num></record></Cite></EndNote>[15], as Kim et al. have shown a similar relationship between antibody titers and circulating plasmablasts following IIV vaccination ADDIN EN.CITE <EndNote><Cite><Author>Kim</Author><Year>2016</Year><RecNum>29</RecNum><DisplayText>[16]</DisplayText><record><rec-number>29</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501182025">29</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Kim, Jin Hyang</author><author>Mishina, Margarita</author><author>Chung, Jessie R</author><author>Cole, Kelly Stefano</author><author>Nowalk, Mary Patricia</author><author>Martin, Judith M</author><author>Spencer, Sarah</author><author>Flannery, Brendan</author><author>Zimmerman, Richard K</author><author>Sambhara, Suryaprakash</author></authors></contributors><titles><title>Cell-mediated immunity against antigenically drifted influenza A (H3N2) viruses in children during a vaccine mismatch season</title><secondary-title>Journal of Infectious Diseases</secondary-title></titles><periodical><full-title>Journal of Infectious Diseases</full-title></periodical><pages>1030-1038</pages><volume>214</volume><number>7</number><dates><year>2016</year></dates><isbn>0022-1899</isbn><urls></urls></record></Cite></EndNote>[16]. More recently, a methodology has been described for isolating and characterizing RNA transcripts in peripheral blood cell subsets compared to whole blood following influenza vaccination ADDIN EN.CITE <EndNote><Cite><Author>Hoek</Author><Year>2015</Year><RecNum>1534</RecNum><DisplayText>[17]</DisplayText><record><rec-number>1534</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1488572311">1534</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Hoek, Kristen L</author><author>Samir, Parimal</author><author>Howard, Leigh M</author><author>Niu, Xinnan</author><author>Prasad, Nripesh</author><author>Galassie, Allison</author><author>Liu, Qi</author><author>Allos, Tara M</author><author>Floyd, Kyle A</author><author>Guo, Yan</author></authors></contributors><titles><title>A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination</title><secondary-title>PloS one</secondary-title></titles><periodical><full-title>PLoS One</full-title><abbr-1>PloS one</abbr-1></periodical><pages>e0118528</pages><volume>10</volume><number>2</number><dates><year>2015</year></dates><isbn>1932-6203</isbn><urls></urls></record></Cite></EndNote>[17]. This approach, combining systems biology and predictive modeling to vaccinology, provides a powerful tool for unraveling the molecular mechanisms of vaccine-induced immunity ADDIN EN.CITE <EndNote><Cite><Author>Pulendran</Author><Year>2014</Year><RecNum>1505</RecNum><DisplayText>[18, 19]</DisplayText><record><rec-number>1505</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1487703684">1505</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Pulendran, Bali</author></authors></contributors><titles><title>Systems vaccinology: probing humanity’s diverse immune systems with vaccines</title><secondary-title>Proceedings of the National Academy of Sciences</secondary-title></titles><periodical><full-title>Proceedings of the National Academy of Sciences</full-title></periodical><pages>12300-12306</pages><volume>111</volume><number>34</number><dates><year>2014</year></dates><isbn>0027-8424</isbn><urls></urls><custom2>PMC4151766</custom2></record></Cite><Cite><Author>Nakaya</Author><Year>2011</Year><RecNum>1506</RecNum><record><rec-number>1506</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1487704165">1506</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Nakaya, Helder I</author><author>Wrammert, Jens</author><author>Lee, Eva K</author><author>Racioppi, Luigi</author><author>Marie-Kunze, Stephanie</author><author>Haining, W Nicholas</author><author>Means, Anthony R</author><author>Kasturi, Sudhir P</author><author>Khan, Nooruddin</author><author>Li, Gui-Mei</author></authors></contributors><titles><title>Systems biology of vaccination for seasonal influenza in humans</title><secondary-title>Nature immunology</secondary-title></titles><periodical><full-title>Nature Immunology</full-title><abbr-1>Nat Immunol</abbr-1></periodical><pages>786-795</pages><volume>12</volume><number>8</number><dates><year>2011</year></dates><isbn>1529-2908</isbn><urls></urls></record></Cite></EndNote>[18, 19]. Systems vaccinology has recently been used to successfully study the immune responses to influenza vaccination in adults PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OYWtheWE8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS

ZWNOdW0+MTUwNjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTQsIDE3LCAxOS0yM108L0Rpc3BsYXlU

ZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MTUwNjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxr

ZXkgYXBwPSJFTiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIg

dGltZXN0YW1wPSIxNDg3NzA0MTY1Ij4xNTA2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBl

IG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhv

cnM+PGF1dGhvcj5OYWtheWEsIEhlbGRlciBJPC9hdXRob3I+PGF1dGhvcj5XcmFtbWVydCwgSmVu

czwvYXV0aG9yPjxhdXRob3I+TGVlLCBFdmEgSzwvYXV0aG9yPjxhdXRob3I+UmFjaW9wcGksIEx1

aWdpPC9hdXRob3I+PGF1dGhvcj5NYXJpZS1LdW56ZSwgU3RlcGhhbmllPC9hdXRob3I+PGF1dGhv

cj5IYWluaW5nLCBXIE5pY2hvbGFzPC9hdXRob3I+PGF1dGhvcj5NZWFucywgQW50aG9ueSBSPC9h

dXRob3I+PGF1dGhvcj5LYXN0dXJpLCBTdWRoaXIgUDwvYXV0aG9yPjxhdXRob3I+S2hhbiwgTm9v

cnVkZGluPC9hdXRob3I+PGF1dGhvcj5MaSwgR3VpLU1laTwvYXV0aG9yPjwvYXV0aG9ycz48L2Nv

bnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5TeXN0ZW1zIGJpb2xvZ3kgb2YgdmFjY2luYXRpb24g

Zm9yIHNlYXNvbmFsIGluZmx1ZW56YSBpbiBodW1hbnM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

TmF0dXJlIGltbXVub2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48

ZnVsbC10aXRsZT5OYXR1cmUgSW1tdW5vbG9neTwvZnVsbC10aXRsZT48YWJici0xPk5hdCBJbW11

bm9sPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxwYWdlcz43ODYtNzk1PC9wYWdlcz48dm9sdW1lPjEy

PC92b2x1bWU+PG51bWJlcj44PC9udW1iZXI+PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PC9kYXRl

cz48aXNibj4xNTI5LTI5MDg8L2lzYm4+PHVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0

ZT48QXV0aG9yPkZ1cm1hbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+PFJlY051bT4xNTI1PC9S

ZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTI1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+

PGtleSBhcHA9IkVOIiBkYi1pZD0iYTJ2dzJ0MDkzczUycmNldmVyMzVkeDBycHMwYXg1OXh2YTBh

IiB0aW1lc3RhbXA9IjE0ODgyMjA2NTMiPjE1MjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5

cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0

aG9ycz48YXV0aG9yPkZ1cm1hbiwgRGF2aWQ8L2F1dGhvcj48YXV0aG9yPkpvamljLCBWbGFkaW1p

cjwvYXV0aG9yPjxhdXRob3I+S2lkZCwgQnJpYW48L2F1dGhvcj48YXV0aG9yPlNoZW7igJBPcnIs

IFNoYWk8L2F1dGhvcj48YXV0aG9yPlByaWNlLCBKb3JkYW48L2F1dGhvcj48YXV0aG9yPkphcnJl

bGwsIEp1c3RpbjwvYXV0aG9yPjxhdXRob3I+VHNlLCBUaWZmYW55PC9hdXRob3I+PGF1dGhvcj5I

dWFuZywgSHVhbmc8L2F1dGhvcj48YXV0aG9yPkx1bmQsIFBlZGVyPC9hdXRob3I+PGF1dGhvcj5N

YWVja2VyLCBIb2xkZW4gVDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVz

Pjx0aXRsZT5BcG9wdG9zaXMgYW5kIG90aGVyIGltbXVuZSBiaW9tYXJrZXJzIHByZWRpY3QgaW5m

bHVlbnphIHZhY2NpbmUgcmVzcG9uc2l2ZW5lc3M8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+TW9s

ZWN1bGFyIHN5c3RlbXMgYmlvbG9neTwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2Rp

Y2FsPjxmdWxsLXRpdGxlPk1vbGVjdWxhciBzeXN0ZW1zIGJpb2xvZ3k8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz42NTk8L3BhZ2VzPjx2b2x1bWU+OTwvdm9sdW1lPjxudW1iZXI+MTwv

bnVtYmVyPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MTc0NC00MjkyPC9p

c2JuPjx1cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CdWNhc2FzPC9B

dXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjE1MDk8L1JlY051bT48cmVjb3JkPjxyZWMt

bnVtYmVyPjE1MDk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk

PSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ4Nzcw

ODAzMCI+MTUwOTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFy

dGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QnVjYXNh

cywgS3Jpc3RpbmUgTDwvYXV0aG9yPjxhdXRob3I+RnJhbmNvLCBMdWlzIE08L2F1dGhvcj48YXV0

aG9yPlNoYXcsIENoYWQgQTwvYXV0aG9yPjxhdXRob3I+QnJheSwgTW9sbHkgUzwvYXV0aG9yPjxh

dXRob3I+V2VsbHMsIEphbmV0IE08L2F1dGhvcj48YXV0aG9yPk5pw7FvLCBEaWFuZTwvYXV0aG9y

PjxhdXRob3I+QXJkZW4sIE5hbmN5PC9hdXRob3I+PGF1dGhvcj5RdWFybGVzLCBKb2huIE08L2F1

dGhvcj48YXV0aG9yPkNvdWNoLCBSb2JlcnQgQjwvYXV0aG9yPjxhdXRob3I+QmVsbW9udCwgSm9o

biBXPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkVhcmx5

IHBhdHRlcm5zIG9mIGdlbmUgZXhwcmVzc2lvbiBjb3JyZWxhdGUgd2l0aCB0aGUgaHVtb3JhbCBp

bW11bmUgcmVzcG9uc2UgdG8gaW5mbHVlbnphIHZhY2NpbmF0aW9uIGluIGh1bWFuczwvdGl0bGU+

PHNlY29uZGFyeS10aXRsZT5Kb3VybmFsIG9mIEluZmVjdGlvdXMgRGlzZWFzZXM8L3NlY29uZGFy

eS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Kb3VybmFsIG9mIEluZmVj

dGlvdXMgRGlzZWFzZXM8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz45MjEtOTI5PC9w

YWdlcz48dm9sdW1lPjIwMzwvdm9sdW1lPjxudW1iZXI+NzwvbnVtYmVyPjxkYXRlcz48eWVhcj4y

MDExPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAyMi0xODk5PC9pc2JuPjx1cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMzMDY4MDMyPC9jdXN0b20yPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlRz

YW5nPC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVjTnVtPjE1MjY8L1JlY051bT48cmVjb3Jk

PjxyZWMtbnVtYmVyPjE1MjY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0i

MTQ4ODIyMTIwNCI+MTUyNjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

VHNhbmcsIEpvaG4gUzwvYXV0aG9yPjxhdXRob3I+U2Nod2FydHpiZXJnLCBQYW1lbGEgTDwvYXV0

aG9yPjxhdXRob3I+S290bGlhcm92LCBZdXJpPC9hdXRob3I+PGF1dGhvcj5CaWFuY290dG8sIEFu

Z2VsaXF1ZTwvYXV0aG9yPjxhdXRob3I+WGllLCBaaGk8L2F1dGhvcj48YXV0aG9yPkdlcm1haW4s

IFJvbmFsZCBOPC9hdXRob3I+PGF1dGhvcj5XYW5nLCBFbmE8L2F1dGhvcj48YXV0aG9yPk9sbmVz

LCBNYXR0aGV3IEo8L2F1dGhvcj48YXV0aG9yPk5hcmF5YW5hbiwgTWFuaWthbmRhbjwvYXV0aG9y

PjxhdXRob3I+R29sZGluZywgSGFuYTwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48

dGl0bGVzPjx0aXRsZT5HbG9iYWwgYW5hbHlzZXMgb2YgaHVtYW4gaW1tdW5lIHZhcmlhdGlvbiBy

ZXZlYWwgYmFzZWxpbmUgcHJlZGljdG9ycyBvZiBwb3N0dmFjY2luYXRpb24gcmVzcG9uc2VzPC90

aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNlbGw8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5DZWxsPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+

NDk5LTUxMzwvcGFnZXM+PHZvbHVtZT4xNTc8L3ZvbHVtZT48bnVtYmVyPjI8L251bWJlcj48ZGF0

ZXM+PHllYXI+MjAxNDwveWVhcj48L2RhdGVzPjxpc2JuPjAwOTItODY3NDwvaXNibj48dXJscz48

L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+SG9lazwvQXV0aG9yPjxZZWFyPjIw

MTU8L1llYXI+PFJlY051bT4xNTM0PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTM0PC9y

ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iYTJ2dzJ0MDkzczUy

cmNldmVyMzVkeDBycHMwYXg1OXh2YTBhIiB0aW1lc3RhbXA9IjE0ODg1NzIzMTEiPjE1MzQ8L2tl

eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkhvZWssIEtyaXN0ZW4gTDwvYXV0

aG9yPjxhdXRob3I+U2FtaXIsIFBhcmltYWw8L2F1dGhvcj48YXV0aG9yPkhvd2FyZCwgTGVpZ2gg

TTwvYXV0aG9yPjxhdXRob3I+Tml1LCBYaW5uYW48L2F1dGhvcj48YXV0aG9yPlByYXNhZCwgTnJp

cGVzaDwvYXV0aG9yPjxhdXRob3I+R2FsYXNzaWUsIEFsbGlzb248L2F1dGhvcj48YXV0aG9yPkxp

dSwgUWk8L2F1dGhvcj48YXV0aG9yPkFsbG9zLCBUYXJhIE08L2F1dGhvcj48YXV0aG9yPkZsb3lk

LCBLeWxlIEE8L2F1dGhvcj48YXV0aG9yPkd1bywgWWFuPC9hdXRob3I+PC9hdXRob3JzPjwvY29u

dHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkEgY2VsbC1iYXNlZCBzeXN0ZW1zIGJpb2xvZ3kgYXNz

ZXNzbWVudCBvZiBodW1hbiBibG9vZCB0byBtb25pdG9yIGltbXVuZSByZXNwb25zZXMgYWZ0ZXIg

aW5mbHVlbnphIHZhY2NpbmF0aW9uPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlBsb1Mgb25lPC9z

ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+UExvUyBPbmU8

L2Z1bGwtdGl0bGU+PGFiYnItMT5QbG9TIG9uZTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFnZXM+

ZTAxMTg1Mjg8L3BhZ2VzPjx2b2x1bWU+MTA8L3ZvbHVtZT48bnVtYmVyPjI8L251bWJlcj48ZGF0

ZXM+PHllYXI+MjAxNTwveWVhcj48L2RhdGVzPjxpc2JuPjE5MzItNjIwMzwvaXNibj48dXJscz48

L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+SGFyYWxhbWJpZXZhPC9BdXRob3I+

PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjE1Mjg8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE1Mjg8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJhMnZ3

MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ4ODIyNTIxOCI+

MTUyODwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SGFyYWxhbWJpZXZh

LCBJYW5hIEg8L2F1dGhvcj48YXV0aG9yPk92c3lhbm5pa292YSwgSW5uYSBHPC9hdXRob3I+PGF1

dGhvcj5LZW5uZWR5LCBSaWNoYXJkIEI8L2F1dGhvcj48YXV0aG9yPlppbW1lcm1hbm4sIE1pY2hh

ZWwgVDwvYXV0aG9yPjxhdXRob3I+R3JpbGwsIERpYW5lIEU8L2F1dGhvcj48YXV0aG9yPk9iZXJn

LCBBbm4gTDwvYXV0aG9yPjxhdXRob3I+UG9sYW5kLCBHcmVnb3J5IEE8L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+VHJhbnNjcmlwdGlvbmFsIHNpZ25hdHVy

ZXMgb2YgaW5mbHVlbnphIEEvSDFOMS1zcGVjaWZpYyBJZ0cgbWVtb3J5LWxpa2UgQiBjZWxsIHJl

c3BvbnNlIGluIG9sZGVyIGluZGl2aWR1YWxzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlZhY2Np

bmU8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5WYWNj

aW5lPC9mdWxsLXRpdGxlPjxhYmJyLTE+VmFjY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFn

ZXM+Mzk5My00MDAyPC9wYWdlcz48dm9sdW1lPjM0PC92b2x1bWU+PG51bWJlcj4zNDwvbnVtYmVy

PjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDI2NC00MTBYPC9pc2JuPjx1

cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5LZW5uZWR5PC9BdXRob3I+

PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjE1MzA8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE1MzA8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJhMnZ3

MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ4ODM4NDE1NyI+

MTUzMDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S2VubmVkeSwgUmlj

aGFyZCBCPC9hdXRob3I+PGF1dGhvcj5PdnN5YW5uaWtvdmEsIElubmEgRzwvYXV0aG9yPjxhdXRo

b3I+SGFyYWxhbWJpZXZhLCBJYW5hIEg8L2F1dGhvcj48YXV0aG9yPk9iZXJnLCBBbm4gTDwvYXV0

aG9yPjxhdXRob3I+WmltbWVybWFubiwgTWljaGFlbCBUPC9hdXRob3I+PGF1dGhvcj5HcmlsbCwg

RGlhbmUgRTwvYXV0aG9yPjxhdXRob3I+UG9sYW5kLCBHcmVnb3J5IEE8L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+SW1tdW5vc2VuZXNjZW5jZS1yZWxhdGVk

IFRyYW5zY3JpcHRvbWljIGFuZCBpbW11bm9sb2dpYyBjaGFuZ2VzIGluIE9sZGVyIGluZGl2aWR1

YWxzIEZvbGxvd2luZyBpbmZsdWVuemEgVmFjY2luYXRpb248L3RpdGxlPjxzZWNvbmRhcnktdGl0

bGU+RnJvbnRpZXJzIGluIEltbXVub2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5Gcm9udCBJbW11bm9sPC9mdWxsLXRpdGxlPjxhYmJyLTE+RnJv

bnRpZXJzIGluIGltbXVub2xvZ3k8L2FiYnItMT48L3BlcmlvZGljYWw+PHBhZ2VzPjEtMTU8L3Bh

Z2VzPjx2b2x1bWU+Nzwvdm9sdW1lPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PHVy

bHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT5odHRwczovL2RvaS5vcmcvMTAuMzM4

OS9maW1tdS4yMDE2LjAwNDUwIDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9D

aXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OYWtheWE8L0F1dGhvcj48WWVhcj4yMDExPC9ZZWFyPjxS

ZWNOdW0+MTUwNjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTQsIDE3LCAxOS0yM108L0Rpc3BsYXlU

ZXh0PjxyZWNvcmQ+PHJlYy1udW1iZXI+MTUwNjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxr

ZXkgYXBwPSJFTiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIg

dGltZXN0YW1wPSIxNDg3NzA0MTY1Ij4xNTA2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBl

IG5hbWU9IkpvdXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhv

cnM+PGF1dGhvcj5OYWtheWEsIEhlbGRlciBJPC9hdXRob3I+PGF1dGhvcj5XcmFtbWVydCwgSmVu

czwvYXV0aG9yPjxhdXRob3I+TGVlLCBFdmEgSzwvYXV0aG9yPjxhdXRob3I+UmFjaW9wcGksIEx1

aWdpPC9hdXRob3I+PGF1dGhvcj5NYXJpZS1LdW56ZSwgU3RlcGhhbmllPC9hdXRob3I+PGF1dGhv

cj5IYWluaW5nLCBXIE5pY2hvbGFzPC9hdXRob3I+PGF1dGhvcj5NZWFucywgQW50aG9ueSBSPC9h

dXRob3I+PGF1dGhvcj5LYXN0dXJpLCBTdWRoaXIgUDwvYXV0aG9yPjxhdXRob3I+S2hhbiwgTm9v

cnVkZGluPC9hdXRob3I+PGF1dGhvcj5MaSwgR3VpLU1laTwvYXV0aG9yPjwvYXV0aG9ycz48L2Nv

bnRyaWJ1dG9ycz48dGl0bGVzPjx0aXRsZT5TeXN0ZW1zIGJpb2xvZ3kgb2YgdmFjY2luYXRpb24g

Zm9yIHNlYXNvbmFsIGluZmx1ZW56YSBpbiBodW1hbnM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+

TmF0dXJlIGltbXVub2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48

ZnVsbC10aXRsZT5OYXR1cmUgSW1tdW5vbG9neTwvZnVsbC10aXRsZT48YWJici0xPk5hdCBJbW11

bm9sPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxwYWdlcz43ODYtNzk1PC9wYWdlcz48dm9sdW1lPjEy

PC92b2x1bWU+PG51bWJlcj44PC9udW1iZXI+PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PC9kYXRl

cz48aXNibj4xNTI5LTI5MDg8L2lzYm4+PHVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0

ZT48QXV0aG9yPkZ1cm1hbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+PFJlY051bT4xNTI1PC9S

ZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTI1PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+

PGtleSBhcHA9IkVOIiBkYi1pZD0iYTJ2dzJ0MDkzczUycmNldmVyMzVkeDBycHMwYXg1OXh2YTBh

IiB0aW1lc3RhbXA9IjE0ODgyMjA2NTMiPjE1MjU8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5

cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0

aG9ycz48YXV0aG9yPkZ1cm1hbiwgRGF2aWQ8L2F1dGhvcj48YXV0aG9yPkpvamljLCBWbGFkaW1p

cjwvYXV0aG9yPjxhdXRob3I+S2lkZCwgQnJpYW48L2F1dGhvcj48YXV0aG9yPlNoZW7igJBPcnIs

IFNoYWk8L2F1dGhvcj48YXV0aG9yPlByaWNlLCBKb3JkYW48L2F1dGhvcj48YXV0aG9yPkphcnJl

bGwsIEp1c3RpbjwvYXV0aG9yPjxhdXRob3I+VHNlLCBUaWZmYW55PC9hdXRob3I+PGF1dGhvcj5I

dWFuZywgSHVhbmc8L2F1dGhvcj48YXV0aG9yPkx1bmQsIFBlZGVyPC9hdXRob3I+PGF1dGhvcj5N

YWVja2VyLCBIb2xkZW4gVDwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48dGl0bGVz

Pjx0aXRsZT5BcG9wdG9zaXMgYW5kIG90aGVyIGltbXVuZSBiaW9tYXJrZXJzIHByZWRpY3QgaW5m

bHVlbnphIHZhY2NpbmUgcmVzcG9uc2l2ZW5lc3M8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+TW9s

ZWN1bGFyIHN5c3RlbXMgYmlvbG9neTwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2Rp

Y2FsPjxmdWxsLXRpdGxlPk1vbGVjdWxhciBzeXN0ZW1zIGJpb2xvZ3k8L2Z1bGwtdGl0bGU+PC9w

ZXJpb2RpY2FsPjxwYWdlcz42NTk8L3BhZ2VzPjx2b2x1bWU+OTwvdm9sdW1lPjxudW1iZXI+MTwv

bnVtYmVyPjxkYXRlcz48eWVhcj4yMDEzPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MTc0NC00MjkyPC9p

c2JuPjx1cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5CdWNhc2FzPC9B

dXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVjTnVtPjE1MDk8L1JlY051bT48cmVjb3JkPjxyZWMt

bnVtYmVyPjE1MDk8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk

PSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ4Nzcw

ODAzMCI+MTUwOTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFy

dGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+QnVjYXNh

cywgS3Jpc3RpbmUgTDwvYXV0aG9yPjxhdXRob3I+RnJhbmNvLCBMdWlzIE08L2F1dGhvcj48YXV0

aG9yPlNoYXcsIENoYWQgQTwvYXV0aG9yPjxhdXRob3I+QnJheSwgTW9sbHkgUzwvYXV0aG9yPjxh

dXRob3I+V2VsbHMsIEphbmV0IE08L2F1dGhvcj48YXV0aG9yPk5pw7FvLCBEaWFuZTwvYXV0aG9y

PjxhdXRob3I+QXJkZW4sIE5hbmN5PC9hdXRob3I+PGF1dGhvcj5RdWFybGVzLCBKb2huIE08L2F1

dGhvcj48YXV0aG9yPkNvdWNoLCBSb2JlcnQgQjwvYXV0aG9yPjxhdXRob3I+QmVsbW9udCwgSm9o

biBXPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkVhcmx5

IHBhdHRlcm5zIG9mIGdlbmUgZXhwcmVzc2lvbiBjb3JyZWxhdGUgd2l0aCB0aGUgaHVtb3JhbCBp

bW11bmUgcmVzcG9uc2UgdG8gaW5mbHVlbnphIHZhY2NpbmF0aW9uIGluIGh1bWFuczwvdGl0bGU+

PHNlY29uZGFyeS10aXRsZT5Kb3VybmFsIG9mIEluZmVjdGlvdXMgRGlzZWFzZXM8L3NlY29uZGFy

eS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Kb3VybmFsIG9mIEluZmVj

dGlvdXMgRGlzZWFzZXM8L2Z1bGwtdGl0bGU+PC9wZXJpb2RpY2FsPjxwYWdlcz45MjEtOTI5PC9w

YWdlcz48dm9sdW1lPjIwMzwvdm9sdW1lPjxudW1iZXI+NzwvbnVtYmVyPjxkYXRlcz48eWVhcj4y

MDExPC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDAyMi0xODk5PC9pc2JuPjx1cmxzPjwvdXJscz48Y3Vz

dG9tMj5QTUMzMDY4MDMyPC9jdXN0b20yPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlRz

YW5nPC9BdXRob3I+PFllYXI+MjAxNDwvWWVhcj48UmVjTnVtPjE1MjY8L1JlY051bT48cmVjb3Jk

PjxyZWMtbnVtYmVyPjE1MjY8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4i

IGRiLWlkPSJhMnZ3MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0i

MTQ4ODIyMTIwNCI+MTUyNjwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3Vy

bmFsIEFydGljbGUiPjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+

VHNhbmcsIEpvaG4gUzwvYXV0aG9yPjxhdXRob3I+U2Nod2FydHpiZXJnLCBQYW1lbGEgTDwvYXV0

aG9yPjxhdXRob3I+S290bGlhcm92LCBZdXJpPC9hdXRob3I+PGF1dGhvcj5CaWFuY290dG8sIEFu

Z2VsaXF1ZTwvYXV0aG9yPjxhdXRob3I+WGllLCBaaGk8L2F1dGhvcj48YXV0aG9yPkdlcm1haW4s

IFJvbmFsZCBOPC9hdXRob3I+PGF1dGhvcj5XYW5nLCBFbmE8L2F1dGhvcj48YXV0aG9yPk9sbmVz

LCBNYXR0aGV3IEo8L2F1dGhvcj48YXV0aG9yPk5hcmF5YW5hbiwgTWFuaWthbmRhbjwvYXV0aG9y

PjxhdXRob3I+R29sZGluZywgSGFuYTwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48

dGl0bGVzPjx0aXRsZT5HbG9iYWwgYW5hbHlzZXMgb2YgaHVtYW4gaW1tdW5lIHZhcmlhdGlvbiBy

ZXZlYWwgYmFzZWxpbmUgcHJlZGljdG9ycyBvZiBwb3N0dmFjY2luYXRpb24gcmVzcG9uc2VzPC90

aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNlbGw8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5DZWxsPC9mdWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+

NDk5LTUxMzwvcGFnZXM+PHZvbHVtZT4xNTc8L3ZvbHVtZT48bnVtYmVyPjI8L251bWJlcj48ZGF0

ZXM+PHllYXI+MjAxNDwveWVhcj48L2RhdGVzPjxpc2JuPjAwOTItODY3NDwvaXNibj48dXJscz48

L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+SG9lazwvQXV0aG9yPjxZZWFyPjIw

MTU8L1llYXI+PFJlY051bT4xNTM0PC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xNTM0PC9y

ZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iYTJ2dzJ0MDkzczUy

cmNldmVyMzVkeDBycHMwYXg1OXh2YTBhIiB0aW1lc3RhbXA9IjE0ODg1NzIzMTEiPjE1MzQ8L2tl

eT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVm

LXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkhvZWssIEtyaXN0ZW4gTDwvYXV0

aG9yPjxhdXRob3I+U2FtaXIsIFBhcmltYWw8L2F1dGhvcj48YXV0aG9yPkhvd2FyZCwgTGVpZ2gg

TTwvYXV0aG9yPjxhdXRob3I+Tml1LCBYaW5uYW48L2F1dGhvcj48YXV0aG9yPlByYXNhZCwgTnJp

cGVzaDwvYXV0aG9yPjxhdXRob3I+R2FsYXNzaWUsIEFsbGlzb248L2F1dGhvcj48YXV0aG9yPkxp

dSwgUWk8L2F1dGhvcj48YXV0aG9yPkFsbG9zLCBUYXJhIE08L2F1dGhvcj48YXV0aG9yPkZsb3lk

LCBLeWxlIEE8L2F1dGhvcj48YXV0aG9yPkd1bywgWWFuPC9hdXRob3I+PC9hdXRob3JzPjwvY29u

dHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkEgY2VsbC1iYXNlZCBzeXN0ZW1zIGJpb2xvZ3kgYXNz

ZXNzbWVudCBvZiBodW1hbiBibG9vZCB0byBtb25pdG9yIGltbXVuZSByZXNwb25zZXMgYWZ0ZXIg

aW5mbHVlbnphIHZhY2NpbmF0aW9uPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlBsb1Mgb25lPC9z

ZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+UExvUyBPbmU8

L2Z1bGwtdGl0bGU+PGFiYnItMT5QbG9TIG9uZTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFnZXM+

ZTAxMTg1Mjg8L3BhZ2VzPjx2b2x1bWU+MTA8L3ZvbHVtZT48bnVtYmVyPjI8L251bWJlcj48ZGF0

ZXM+PHllYXI+MjAxNTwveWVhcj48L2RhdGVzPjxpc2JuPjE5MzItNjIwMzwvaXNibj48dXJscz48

L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+SGFyYWxhbWJpZXZhPC9BdXRob3I+

PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjE1Mjg8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE1Mjg8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJhMnZ3

MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ4ODIyNTIxOCI+

MTUyODwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+SGFyYWxhbWJpZXZh

LCBJYW5hIEg8L2F1dGhvcj48YXV0aG9yPk92c3lhbm5pa292YSwgSW5uYSBHPC9hdXRob3I+PGF1

dGhvcj5LZW5uZWR5LCBSaWNoYXJkIEI8L2F1dGhvcj48YXV0aG9yPlppbW1lcm1hbm4sIE1pY2hh

ZWwgVDwvYXV0aG9yPjxhdXRob3I+R3JpbGwsIERpYW5lIEU8L2F1dGhvcj48YXV0aG9yPk9iZXJn

LCBBbm4gTDwvYXV0aG9yPjxhdXRob3I+UG9sYW5kLCBHcmVnb3J5IEE8L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+VHJhbnNjcmlwdGlvbmFsIHNpZ25hdHVy

ZXMgb2YgaW5mbHVlbnphIEEvSDFOMS1zcGVjaWZpYyBJZ0cgbWVtb3J5LWxpa2UgQiBjZWxsIHJl

c3BvbnNlIGluIG9sZGVyIGluZGl2aWR1YWxzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPlZhY2Np

bmU8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5WYWNj

aW5lPC9mdWxsLXRpdGxlPjxhYmJyLTE+VmFjY2luZTwvYWJici0xPjwvcGVyaW9kaWNhbD48cGFn

ZXM+Mzk5My00MDAyPC9wYWdlcz48dm9sdW1lPjM0PC92b2x1bWU+PG51bWJlcj4zNDwvbnVtYmVy

PjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MDI2NC00MTBYPC9pc2JuPjx1

cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PENpdGU+PEF1dGhvcj5LZW5uZWR5PC9BdXRob3I+

PFllYXI+MjAxNjwvWWVhcj48UmVjTnVtPjE1MzA8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE1MzA8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJhMnZ3

MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ4ODM4NDE1NyI+

MTUzMDwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+S2VubmVkeSwgUmlj

aGFyZCBCPC9hdXRob3I+PGF1dGhvcj5PdnN5YW5uaWtvdmEsIElubmEgRzwvYXV0aG9yPjxhdXRo

b3I+SGFyYWxhbWJpZXZhLCBJYW5hIEg8L2F1dGhvcj48YXV0aG9yPk9iZXJnLCBBbm4gTDwvYXV0

aG9yPjxhdXRob3I+WmltbWVybWFubiwgTWljaGFlbCBUPC9hdXRob3I+PGF1dGhvcj5HcmlsbCwg

RGlhbmUgRTwvYXV0aG9yPjxhdXRob3I+UG9sYW5kLCBHcmVnb3J5IEE8L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+SW1tdW5vc2VuZXNjZW5jZS1yZWxhdGVk

IFRyYW5zY3JpcHRvbWljIGFuZCBpbW11bm9sb2dpYyBjaGFuZ2VzIGluIE9sZGVyIGluZGl2aWR1

YWxzIEZvbGxvd2luZyBpbmZsdWVuemEgVmFjY2luYXRpb248L3RpdGxlPjxzZWNvbmRhcnktdGl0

bGU+RnJvbnRpZXJzIGluIEltbXVub2xvZ3k8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48cGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5Gcm9udCBJbW11bm9sPC9mdWxsLXRpdGxlPjxhYmJyLTE+RnJv

bnRpZXJzIGluIGltbXVub2xvZ3k8L2FiYnItMT48L3BlcmlvZGljYWw+PHBhZ2VzPjEtMTU8L3Bh

Z2VzPjx2b2x1bWU+Nzwvdm9sdW1lPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFyPjwvZGF0ZXM+PHVy

bHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT5odHRwczovL2RvaS5vcmcvMTAuMzM4

OS9maW1tdS4yMDE2LjAwNDUwIDwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9D

aXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA [14, 17, 19-23]. The current study adds to the body of systems vaccinology literature for understanding immune response to influenza vaccine among children and highlights the many differences between responses to LAIV and IIV. It is important to note that these differences may not reflect potential differences in response to infection with wild type influenza compared with LAIV PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5aaHU8L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNO

dW0+MTgyMjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTMsIDI0XTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4xODIyPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iYTJ2dzJ0MDkzczUycmNldmVyMzVkeDBycHMwYXg1OXh2YTBhIiB0aW1lc3RhbXA9

IjE0OTgyMzc3NjQiPjE4MjI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlpodSwgV2VpPC9hdXRob3I+PGF1dGhvcj5IaWdncywgQnJhbmRvbiBXPC9hdXRob3I+PGF1dGhv

cj5Nb3JlaG91c2UsIENocmlzPC9hdXRob3I+PGF1dGhvcj5TdHJlaWNoZXIsIEthdGllPC9hdXRo

b3I+PGF1dGhvcj5BbWJyb3NlLCBDaHJpc3RvcGhlciBTPC9hdXRob3I+PGF1dGhvcj5Xb28sIEpl

bm5pZmVyPC9hdXRob3I+PGF1dGhvcj5LZW1ibGUsIEdlb3JnZSBXPC9hdXRob3I+PGF1dGhvcj5K

YWxsYWwsIEJhaGlqYTwvYXV0aG9yPjxhdXRob3I+WWFvLCBZaWhvbmc8L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+QSB3aG9sZSBnZW5vbWUgdHJhbnNjcmlw

dGlvbmFsIGFuYWx5c2lzIG9mIHRoZSBlYXJseSBpbW11bmUgcmVzcG9uc2UgaW5kdWNlZCBieSBs

aXZlIGF0dGVudWF0ZWQgYW5kIGluYWN0aXZhdGVkIGluZmx1ZW56YSB2YWNjaW5lcyBpbiB5b3Vu

ZyBjaGlsZHJlbjwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5WYWNjaW5lPC9zZWNvbmRhcnktdGl0

bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+VmFjY2luZTwvZnVsbC10aXRsZT48

YWJici0xPlZhY2NpbmU8L2FiYnItMT48L3BlcmlvZGljYWw+PHBhZ2VzPjI4NjUtMjg3NjwvcGFn

ZXM+PHZvbHVtZT4yODwvdm9sdW1lPjxudW1iZXI+MTY8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAx

MDwveWVhcj48L2RhdGVzPjxpc2JuPjAyNjQtNDEwWDwvaXNibj48dXJscz48L3VybHM+PC9yZWNv

cmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+RmlzY2hlciBJSTwvQXV0aG9yPjxZZWFyPjIwMTQ8L1ll

YXI+PFJlY051bT4xODIzPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xODIzPC9yZWMtbnVt

YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iYTJ2dzJ0MDkzczUycmNldmVy

MzVkeDBycHMwYXg1OXh2YTBhIiB0aW1lc3RhbXA9IjE0OTgyMzc5MDkiPjE4MjM8L2tleT48L2Zv

cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+

PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpc2NoZXIgSUksIFdpbGxpYW0gQTwvYXV0

aG9yPjxhdXRob3I+Q2hhc29uLCBLZWxseSBEPC9hdXRob3I+PGF1dGhvcj5CcmlnaHRvbiwgTWlz

c3k8L2F1dGhvcj48YXV0aG9yPkphc3BlcnMsIElsb25hPC9hdXRob3I+PC9hdXRob3JzPjwvY29u

dHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkxpdmUgYXR0ZW51YXRlZCBpbmZsdWVuemEgdmFjY2lu

ZSBzdHJhaW5zIGVsaWNpdCBhIGdyZWF0ZXIgaW5uYXRlIGltbXVuZSByZXNwb25zZSB0aGFuIGFu

dGlnZW5pY2FsbHktbWF0Y2hlZCBzZWFzb25hbCBpbmZsdWVuemEgdmlydXNlcyBkdXJpbmcgaW5m

ZWN0aW9uIG9mIGh1bWFuIG5hc2FsIGVwaXRoZWxpYWwgY2VsbCBjdWx0dXJlczwvdGl0bGU+PHNl

Y29uZGFyeS10aXRsZT5WYWNjaW5lPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+VmFjY2luZTwvZnVsbC10aXRsZT48YWJici0xPlZhY2NpbmU8L2FiYnIt

MT48L3BlcmlvZGljYWw+PHBhZ2VzPjE3NjEtMTc2NzwvcGFnZXM+PHZvbHVtZT4zMjwvdm9sdW1l

PjxudW1iZXI+MTU8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48L2RhdGVzPjxpc2Ju

PjAyNjQtNDEwWDwvaXNibj48dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5aaHU8L0F1dGhvcj48WWVhcj4yMDEwPC9ZZWFyPjxSZWNO

dW0+MTgyMjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTMsIDI0XTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4xODIyPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVO

IiBkYi1pZD0iYTJ2dzJ0MDkzczUycmNldmVyMzVkeDBycHMwYXg1OXh2YTBhIiB0aW1lc3RhbXA9

IjE0OTgyMzc3NjQiPjE4MjI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91

cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9y

PlpodSwgV2VpPC9hdXRob3I+PGF1dGhvcj5IaWdncywgQnJhbmRvbiBXPC9hdXRob3I+PGF1dGhv

cj5Nb3JlaG91c2UsIENocmlzPC9hdXRob3I+PGF1dGhvcj5TdHJlaWNoZXIsIEthdGllPC9hdXRo

b3I+PGF1dGhvcj5BbWJyb3NlLCBDaHJpc3RvcGhlciBTPC9hdXRob3I+PGF1dGhvcj5Xb28sIEpl

bm5pZmVyPC9hdXRob3I+PGF1dGhvcj5LZW1ibGUsIEdlb3JnZSBXPC9hdXRob3I+PGF1dGhvcj5K

YWxsYWwsIEJhaGlqYTwvYXV0aG9yPjxhdXRob3I+WWFvLCBZaWhvbmc8L2F1dGhvcj48L2F1dGhv

cnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+QSB3aG9sZSBnZW5vbWUgdHJhbnNjcmlw

dGlvbmFsIGFuYWx5c2lzIG9mIHRoZSBlYXJseSBpbW11bmUgcmVzcG9uc2UgaW5kdWNlZCBieSBs

aXZlIGF0dGVudWF0ZWQgYW5kIGluYWN0aXZhdGVkIGluZmx1ZW56YSB2YWNjaW5lcyBpbiB5b3Vu

ZyBjaGlsZHJlbjwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5WYWNjaW5lPC9zZWNvbmRhcnktdGl0

bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+VmFjY2luZTwvZnVsbC10aXRsZT48

YWJici0xPlZhY2NpbmU8L2FiYnItMT48L3BlcmlvZGljYWw+PHBhZ2VzPjI4NjUtMjg3NjwvcGFn

ZXM+PHZvbHVtZT4yODwvdm9sdW1lPjxudW1iZXI+MTY8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAx

MDwveWVhcj48L2RhdGVzPjxpc2JuPjAyNjQtNDEwWDwvaXNibj48dXJscz48L3VybHM+PC9yZWNv

cmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+RmlzY2hlciBJSTwvQXV0aG9yPjxZZWFyPjIwMTQ8L1ll

YXI+PFJlY051bT4xODIzPC9SZWNOdW0+PHJlY29yZD48cmVjLW51bWJlcj4xODIzPC9yZWMtbnVt

YmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1pZD0iYTJ2dzJ0MDkzczUycmNldmVy

MzVkeDBycHMwYXg1OXh2YTBhIiB0aW1lc3RhbXA9IjE0OTgyMzc5MDkiPjE4MjM8L2tleT48L2Zv

cmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+

PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZpc2NoZXIgSUksIFdpbGxpYW0gQTwvYXV0

aG9yPjxhdXRob3I+Q2hhc29uLCBLZWxseSBEPC9hdXRob3I+PGF1dGhvcj5CcmlnaHRvbiwgTWlz

c3k8L2F1dGhvcj48YXV0aG9yPkphc3BlcnMsIElsb25hPC9hdXRob3I+PC9hdXRob3JzPjwvY29u

dHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkxpdmUgYXR0ZW51YXRlZCBpbmZsdWVuemEgdmFjY2lu

ZSBzdHJhaW5zIGVsaWNpdCBhIGdyZWF0ZXIgaW5uYXRlIGltbXVuZSByZXNwb25zZSB0aGFuIGFu

dGlnZW5pY2FsbHktbWF0Y2hlZCBzZWFzb25hbCBpbmZsdWVuemEgdmlydXNlcyBkdXJpbmcgaW5m

ZWN0aW9uIG9mIGh1bWFuIG5hc2FsIGVwaXRoZWxpYWwgY2VsbCBjdWx0dXJlczwvdGl0bGU+PHNl

Y29uZGFyeS10aXRsZT5WYWNjaW5lPC9zZWNvbmRhcnktdGl0bGU+PC90aXRsZXM+PHBlcmlvZGlj

YWw+PGZ1bGwtdGl0bGU+VmFjY2luZTwvZnVsbC10aXRsZT48YWJici0xPlZhY2NpbmU8L2FiYnIt

MT48L3BlcmlvZGljYWw+PHBhZ2VzPjE3NjEtMTc2NzwvcGFnZXM+PHZvbHVtZT4zMjwvdm9sdW1l

PjxudW1iZXI+MTU8L251bWJlcj48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48L2RhdGVzPjxpc2Ju

PjAyNjQtNDEwWDwvaXNibj48dXJscz48L3VybHM+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT4A

ADDIN EN.CITE.DATA [13, 24].Strengths and Limitations The primary strength of this study is that it uses one of few data sets available on the transcriptional response to the 2015-2016 influenza vaccine when LAIV had limited effectiveness but was still widely being used. Further, many of the children sampled had been enrolled in the study for two or more years, providing a unique opportunity to evaluate and compare immunity elicited by LAIV to that of IIV and the impact of prior vaccination. Investigators at Stanford confirmed limitations of using current serum antibody assays to monitor vaccine effectiveness, demonstrating that prior vaccination priming was critical for the effective immune response to the current vaccine year as measured by plasmablast and other more in-depth immune responses ADDIN EN.CITE <EndNote><Cite><Author>He</Author><Year>2014</Year><RecNum>1827</RecNum><DisplayText>[25]</DisplayText><record><rec-number>1827</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1499275312">1827</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>He, Xiao-Song</author><author>Holmes, Tyson H</author><author>Sanyal, Mrinmoy</author><author>Albrecht, Randy A</author><author>García-Sastre, Adolfo</author><author>Dekker, Cornelia L</author><author>Davis, Mark M</author><author>Greenberg, Harry B</author></authors></contributors><titles><title>Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination</title><secondary-title>The Journal of infectious diseases</secondary-title></titles><periodical><full-title>J Infect Dis</full-title><abbr-1>The Journal of infectious diseases</abbr-1></periodical><pages>1051-1059</pages><volume>211</volume><number>7</number><dates><year>2014</year></dates><isbn>0022-1899</isbn><urls></urls></record></Cite></EndNote>[25]. Of note, a larger proportion of children received IIV compared to LAIV, as this was a convenience sample of children for whom sufficient specimen volume for both Day 0 and Day 7 were available. A limited set of pre-selected genes was used for testing; however, this selection was based on the knowledge of local experts and review of the medical literature of prior similar studies. It is possible that a larger sample size or examination of other genes would generate additional results and that another mechanism explains the differences in response. Given the limitations in sample size, we report both P and Q values in Table 2, thereby allowing readers to determine which they prefer. Furthermore, these findings should be evaluated in the context of a broad spectrum of humoral antibody responses (IgG and IgA), protein expression and cell mediated responses in the same population. It has recently been suggested that obesity and exposure to cigarette smoke may each be associated with immune dysfunction and may affect response to vaccines PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZW5nPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVj

TnVtPjE4MjY8L1JlY051bT48RGlzcGxheVRleHQ+WzI2LCAyN108L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MTgyNjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0YW1w

PSIxNDk4MjM4MDM4Ij4xODI2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv

dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv

cj5GZW5nLCBZYW48L2F1dGhvcj48YXV0aG9yPktvbmcsIFlpbmc8L2F1dGhvcj48YXV0aG9yPkJh

cm5lcywgUGV0ZXIgRjwvYXV0aG9yPjxhdXRob3I+SHVhbmcsIEZhbmctRmFuZzwvYXV0aG9yPjxh

dXRob3I+S2x1Y2FyLCBQZXRlcjwvYXV0aG9yPjxhdXRob3I+V2FuZywgWGlzaGVuZzwvYXV0aG9y

PjxhdXRob3I+U2FtdGVuLCBCdWthPC9hdXRob3I+PGF1dGhvcj5TZW5ndXB0YSwgTWF5YW1pPC9h

dXRob3I+PGF1dGhvcj5NYWNob25hLCBCcnVjZTwvYXV0aG9yPjxhdXRob3I+RG9uaXMsIFJ1YmVu

PC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkV4cG9zdXJl

IHRvIGNpZ2FyZXR0ZSBzbW9rZSBpbmhpYml0cyB0aGUgcHVsbW9uYXJ5IFQtY2VsbCByZXNwb25z

ZSB0byBpbmZsdWVuemEgdmlydXMgYW5kIE15Y29iYWN0ZXJpdW0gdHViZXJjdWxvc2lzPC90aXRs

ZT48c2Vjb25kYXJ5LXRpdGxlPkluZmVjdGlvbiBhbmQgaW1tdW5pdHk8L3NlY29uZGFyeS10aXRs

ZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbmZlY3Rpb24gYW5kIEltbXVuaXR5

PC9mdWxsLXRpdGxlPjxhYmJyLTE+SW5mZWN0IEltbXVuPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxw

YWdlcz4yMjktMjM3PC9wYWdlcz48dm9sdW1lPjc5PC92b2x1bWU+PG51bWJlcj4xPC9udW1iZXI+

PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PC9kYXRlcz48aXNibj4wMDE5LTk1Njc8L2lzYm4+PHVy

bHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlNoZXJpZGFuPC9BdXRob3I+

PFllYXI+MjAxMjwvWWVhcj48UmVjTnVtPjE4MjU8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE4MjU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJhMnZ3

MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ5ODIzNzk3MiI+

MTgyNTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+U2hlcmlkYW4sIFBh

dHJpY2lhIEE8L2F1dGhvcj48YXV0aG9yPlBhaWNoLCBIZWF0aGVyIEE8L2F1dGhvcj48YXV0aG9y

PkhhbmR5LCBKZWFuPC9hdXRob3I+PGF1dGhvcj5LYXJsc3NvbiwgRXJpayBBPC9hdXRob3I+PGF1

dGhvcj5IdWRnZW5zLCBNaWNoYWVsIEc8L2F1dGhvcj48YXV0aG9yPlNhbW1vbiwgQWlsZWVuIEI8

L2F1dGhvcj48YXV0aG9yPkhvbGxhbmQsIExhcmEgQTwvYXV0aG9yPjxhdXRob3I+V2VpciwgU2Ft

dWVsPC9hdXRob3I+PGF1dGhvcj5Ob2FoLCBUZXJyeSBMPC9hdXRob3I+PGF1dGhvcj5CZWNrLCBN

ZWxpbmRhIEE8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+

T2Jlc2l0eSBpcyBhc3NvY2lhdGVkIHdpdGggaW1wYWlyZWQgaW1tdW5lIHJlc3BvbnNlIHRvIGlu

Zmx1ZW56YSB2YWNjaW5hdGlvbiBpbiBodW1hbnM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SW50

ZXJuYXRpb25hbCBqb3VybmFsIG9mIG9iZXNpdHk8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnRlcm5hdGlvbmFsIGpvdXJuYWwgb2Ygb2Jlc2l0eTwv

ZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEwNzItMTA3NzwvcGFnZXM+PHZvbHVtZT4z

Njwvdm9sdW1lPjxudW1iZXI+ODwvbnVtYmVyPjxkYXRlcz48eWVhcj4yMDEyPC95ZWFyPjwvZGF0

ZXM+PGlzYm4+MDMwNy0wNTY1PC9pc2JuPjx1cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9F

bmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZW5nPC9BdXRob3I+PFllYXI+MjAxMTwvWWVhcj48UmVj

TnVtPjE4MjY8L1JlY051bT48RGlzcGxheVRleHQ+WzI2LCAyN108L0Rpc3BsYXlUZXh0PjxyZWNv

cmQ+PHJlYy1udW1iZXI+MTgyNjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJF

TiIgZGItaWQ9ImEydncydDA5M3M1MnJjZXZlcjM1ZHgwcnBzMGF4NTl4dmEwYSIgdGltZXN0YW1w

PSIxNDk4MjM4MDM4Ij4xODI2PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9Ikpv

dXJuYWwgQXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhv

cj5GZW5nLCBZYW48L2F1dGhvcj48YXV0aG9yPktvbmcsIFlpbmc8L2F1dGhvcj48YXV0aG9yPkJh

cm5lcywgUGV0ZXIgRjwvYXV0aG9yPjxhdXRob3I+SHVhbmcsIEZhbmctRmFuZzwvYXV0aG9yPjxh

dXRob3I+S2x1Y2FyLCBQZXRlcjwvYXV0aG9yPjxhdXRob3I+V2FuZywgWGlzaGVuZzwvYXV0aG9y

PjxhdXRob3I+U2FtdGVuLCBCdWthPC9hdXRob3I+PGF1dGhvcj5TZW5ndXB0YSwgTWF5YW1pPC9h

dXRob3I+PGF1dGhvcj5NYWNob25hLCBCcnVjZTwvYXV0aG9yPjxhdXRob3I+RG9uaXMsIFJ1YmVu

PC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0aXRsZXM+PHRpdGxlPkV4cG9zdXJl

IHRvIGNpZ2FyZXR0ZSBzbW9rZSBpbmhpYml0cyB0aGUgcHVsbW9uYXJ5IFQtY2VsbCByZXNwb25z

ZSB0byBpbmZsdWVuemEgdmlydXMgYW5kIE15Y29iYWN0ZXJpdW0gdHViZXJjdWxvc2lzPC90aXRs

ZT48c2Vjb25kYXJ5LXRpdGxlPkluZmVjdGlvbiBhbmQgaW1tdW5pdHk8L3NlY29uZGFyeS10aXRs

ZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbmZlY3Rpb24gYW5kIEltbXVuaXR5

PC9mdWxsLXRpdGxlPjxhYmJyLTE+SW5mZWN0IEltbXVuPC9hYmJyLTE+PC9wZXJpb2RpY2FsPjxw

YWdlcz4yMjktMjM3PC9wYWdlcz48dm9sdW1lPjc5PC92b2x1bWU+PG51bWJlcj4xPC9udW1iZXI+

PGRhdGVzPjx5ZWFyPjIwMTE8L3llYXI+PC9kYXRlcz48aXNibj4wMDE5LTk1Njc8L2lzYm4+PHVy

bHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48Q2l0ZT48QXV0aG9yPlNoZXJpZGFuPC9BdXRob3I+

PFllYXI+MjAxMjwvWWVhcj48UmVjTnVtPjE4MjU8L1JlY051bT48cmVjb3JkPjxyZWMtbnVtYmVy

PjE4MjU8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJhMnZ3

MnQwOTNzNTJyY2V2ZXIzNWR4MHJwczBheDU5eHZhMGEiIHRpbWVzdGFtcD0iMTQ5ODIzNzk3MiI+

MTgyNTwva2V5PjwvZm9yZWlnbi1rZXlzPjxyZWYtdHlwZSBuYW1lPSJKb3VybmFsIEFydGljbGUi

PjE3PC9yZWYtdHlwZT48Y29udHJpYnV0b3JzPjxhdXRob3JzPjxhdXRob3I+U2hlcmlkYW4sIFBh

dHJpY2lhIEE8L2F1dGhvcj48YXV0aG9yPlBhaWNoLCBIZWF0aGVyIEE8L2F1dGhvcj48YXV0aG9y

PkhhbmR5LCBKZWFuPC9hdXRob3I+PGF1dGhvcj5LYXJsc3NvbiwgRXJpayBBPC9hdXRob3I+PGF1

dGhvcj5IdWRnZW5zLCBNaWNoYWVsIEc8L2F1dGhvcj48YXV0aG9yPlNhbW1vbiwgQWlsZWVuIEI8

L2F1dGhvcj48YXV0aG9yPkhvbGxhbmQsIExhcmEgQTwvYXV0aG9yPjxhdXRob3I+V2VpciwgU2Ft

dWVsPC9hdXRob3I+PGF1dGhvcj5Ob2FoLCBUZXJyeSBMPC9hdXRob3I+PGF1dGhvcj5CZWNrLCBN

ZWxpbmRhIEE8L2F1dGhvcj48L2F1dGhvcnM+PC9jb250cmlidXRvcnM+PHRpdGxlcz48dGl0bGU+

T2Jlc2l0eSBpcyBhc3NvY2lhdGVkIHdpdGggaW1wYWlyZWQgaW1tdW5lIHJlc3BvbnNlIHRvIGlu

Zmx1ZW56YSB2YWNjaW5hdGlvbiBpbiBodW1hbnM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+SW50

ZXJuYXRpb25hbCBqb3VybmFsIG9mIG9iZXNpdHk8L3NlY29uZGFyeS10aXRsZT48L3RpdGxlcz48

cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5JbnRlcm5hdGlvbmFsIGpvdXJuYWwgb2Ygb2Jlc2l0eTwv

ZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjEwNzItMTA3NzwvcGFnZXM+PHZvbHVtZT4z

Njwvdm9sdW1lPjxudW1iZXI+ODwvbnVtYmVyPjxkYXRlcz48eWVhcj4yMDEyPC95ZWFyPjwvZGF0

ZXM+PGlzYm4+MDMwNy0wNTY1PC9pc2JuPjx1cmxzPjwvdXJscz48L3JlY29yZD48L0NpdGU+PC9F

bmROb3RlPgB=

ADDIN EN.CITE.DATA [26, 27]. However, Smit et al. did not demonstrate a difference in rates of PCR confirmed influenza in vaccinated obese children compared with vaccinated non-obese children ADDIN EN.CITE <EndNote><Cite><Author>Smit</Author><Year>2016</Year><RecNum>1824</RecNum><DisplayText>[28]</DisplayText><record><rec-number>1824</rec-number><foreign-keys><key app="EN" db-id="a2vw2t093s52rcever35dx0rps0ax59xva0a" timestamp="1498237931">1824</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Smit, Michael A</author><author>Wang, Hai-Lin</author><author>Kim, Edward</author><author>Barragan, Noel</author><author>Aldrovandi, Grace M</author><author>El Amin, Alvin Nelson</author><author>Mascola, Laurene</author><author>Pannaraj, Pia S</author></authors></contributors><titles><title>Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children</title><secondary-title>The Pediatric infectious disease journal</secondary-title></titles><periodical><full-title>Pediatr Infect Dis J</full-title><abbr-1>The Pediatric infectious disease journal</abbr-1></periodical><pages>440-445</pages><volume>35</volume><number>4</number><dates><year>2016</year></dates><isbn>0891-3668</isbn><urls></urls></record></Cite></EndNote>[28]. The current study was not large enough to examine these variables and future studies should further evaluate these relationships. Additional factors that may affect VE, which we could not evaluate in our study, include vaccine match and mutations due to passage of the vaccine virus in eggs during manufacturing ADDIN EN.CITE <EndNote><Cite><Author>Xie</Author><Year>2015</Year><RecNum>103</RecNum><DisplayText>[29]</DisplayText><record><rec-number>103</rec-number><foreign-keys><key app="EN" db-id="wrd0fspz9dzs9pedvr2x0xxftd2frs0vxv5z" timestamp="1501877157">103</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Xie, Hang</author><author>Wan, Xiu-Feng</author><author>Ye, Zhiping</author><author>Plant, Ewan P</author><author>Zhao, Yangqing</author><author>Xu, Yifei</author><author>Li, Xing</author><author>Finch, Courtney</author><author>Zhao, Nan</author><author>Kawano, Toshiaki</author></authors></contributors><titles><title>H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps</title><secondary-title>Scientific reports</secondary-title></titles><periodical><full-title>Scientific reports</full-title></periodical><volume>5</volume><dates><year>2015</year></dates><urls></urls></record></Cite></EndNote>[29].ConclusionDifferential gene expressions were observed between children who received the 2015-16 IIV and those who received the LAIV. These transcriptional profiles help to elucidate the differences in the immune response to influenza vaccines and may help to explain why LAIV has not been as effective as IIV in recent years.Funding: This work was supported by the Centers for Disease Control and Prevention (CDC), through cooperative agreements with the University of Pittsburgh [grant U01 IP000467 and IP001035] and by the National Institutes of Health (NIH) [grant UL1 TR001857] to the University of Pittsburgh. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC or the NIH.Potential Conflict of Interest: Drs. Zimmerman has research funding from Sanofi Pasteur, Inc. Pfizer, Inc. and Merck & Co., Inc. Dr. Lin has research funding from Sanofi Pasteur, Inc. and Merck & Co, Inc. Dr. Nowalk has research funding from Pfizer, Inc. and Merck & Co., Inc. Dr. Alcorn has research funding from MedImmune, LLC and Merck & Co.References ADDIN EN.REFLIST 1.Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP et al: Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. The Journal of infectious diseases 2016.2.Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M: 2014–2015 influenza vaccine effectiveness in the United States by vaccine type. Clinical Infectious Diseases 2016, 63(12):1564-1573.3.Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM et al: Influenza Vaccine Effectiveness in the 2011-2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. Clinical Infectious Diseases 2014, 58(3):319-327.4.Osterholm MT, Kelley NS, Sommer A, Belongia EA: Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious diseases 2012, 12(1):36-44.5.Cotter CR, Jin H, Chen Z: A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS pathogens 2014, 10(1):e1003831.6.O'Donnell CD, Vogel L, Matsuoka Y, Jin H, Subbarao K: The matrix gene segment destabilizes the acid and thermal stability of the hemagglutinin of pandemic live attenuated influenza virus vaccines. Journal of virology 2014, 88(21):12374-12384.7.Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, Martin ET, Belongia EA, McLean HQ, Gaglani M et al: Influenza Vaccine Effectiveness in the United States — 2015/16 Season. New England Journal of Medicine 2017, In Press.8.Levine MZ, Martin JM, Gross FL, Jefferson S, Cole KS, Archibald CA, Nowalk MP, Susick M, Moehling K, Spencer S: Neutralizing Antibody Responses to Antigenically Drifted Influenza A (H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination. Clinical and Vaccine Immunology 2016, 23(10):831-839.9.Russell K: Update: Influenza Activity—United States, October 4, 2015–February 6, 2016. MMWR Morbidity and mortality weekly report 2016, 65.10.Illumina: TruSeq Targeted RNA Expression Reference Guide Revision C. In. San Diego CA; 2016.11.Cao RG, Suarez NM, Obermoser G, Lopez SM, Flano E, Mertz SE, Albrecht RA, García-Sastre A, Mejias A, Xu H: Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. Journal of Infectious Diseases 2014, 210(2):224-233.12.Dou Y, Fu B, Sun R, Li W, Hu W, Tian Z, Wei H: Influenza vaccine induces intracellular immune memory of human NK cells. PloS one 2015, 10(3):e0121258.13.Zhu W, Higgs BW, Morehouse C, Streicher K, Ambrose CS, Woo J, Kemble GW, Jallal B, Yao Y: A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 2010, 28(16):2865-2876.14.Bucasas KL, Franco LM, Shaw CA, Bray MS, Wells JM, Ni?o D, Arden N, Quarles JM, Couch RB, Belmont JW: Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. Journal of Infectious Diseases 2011, 203(7):921-929.15.Tan Y, Tamayo P, Nakaya H, Pulendran B, Mesirov JP, Haining WN: Gene signatures related to B-cell proliferation predict influenza vaccine-induced antibody response. European Journal of Immunology 2014, 44(1):285-295.16.Kim JH, Mishina M, Chung JR, Cole KS, Nowalk MP, Martin JM, Spencer S, Flannery B, Zimmerman RK, Sambhara S: Cell-mediated immunity against antigenically drifted influenza A (H3N2) viruses in children during a vaccine mismatch season. Journal of Infectious Diseases 2016, 214(7):1030-1038.17.Hoek KL, Samir P, Howard LM, Niu X, Prasad N, Galassie A, Liu Q, Allos TM, Floyd KA, Guo Y: A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination. PloS one 2015, 10(2):e0118528.18.Pulendran B: Systems vaccinology: probing humanity’s diverse immune systems with vaccines. Proceedings of the National Academy of Sciences 2014, 111(34):12300-12306.19.Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li G-M: Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011, 12(8):786-795.20.Furman D, Jojic V, Kidd B, Shen‐Orr S, Price J, Jarrell J, Tse T, Huang H, Lund P, Maecker HT: Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Molecular systems biology 2013, 9(1):659.21.Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, Wang E, Olnes MJ, Narayanan M, Golding H: Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 2014, 157(2):499-513.22.Haralambieva IH, Ovsyannikova IG, Kennedy RB, Zimmermann MT, Grill DE, Oberg AL, Poland GA: Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals. Vaccine 2016, 34(34):3993-4002.23.Kennedy RB, Ovsyannikova IG, Haralambieva IH, Oberg AL, Zimmermann MT, Grill DE, Poland GA: Immunosenescence-related Transcriptomic and immunologic changes in Older individuals Following influenza Vaccination. Frontiers in immunology 2016, 7:1-15.24.Fischer II WA, Chason KD, Brighton M, Jaspers I: Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures. Vaccine 2014, 32(15):1761-1767.25.He X-S, Holmes TH, Sanyal M, Albrecht RA, García-Sastre A, Dekker CL, Davis MM, Greenberg HB: Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination. The Journal of infectious diseases 2014, 211(7):1051-1059.26.Feng Y, Kong Y, Barnes PF, Huang F-F, Klucar P, Wang X, Samten B, Sengupta M, Machona B, Donis R: Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and Mycobacterium tuberculosis. Infect Immun 2011, 79(1):229-237.27.Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB, Holland LA, Weir S, Noah TL, Beck MA: Obesity is associated with impaired immune response to influenza vaccination in humans. International journal of obesity 2012, 36(8):1072-1077.28.Smit MA, Wang H-L, Kim E, Barragan N, Aldrovandi GM, El Amin AN, Mascola L, Pannaraj PS: Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children. The Pediatric infectious disease journal 2016, 35(4):440-445.29.Xie H, Wan X-F, Ye Z, Plant EP, Zhao Y, Xu Y, Li X, Finch C, Zhao N, Kawano T: H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Scientific reports 2015, 5.Table 1. Demographic Characteristics of Participants Overall and by 2015-2016 Influenza Vaccine TypeVariableTotalN=72LAIV*N=26IIV**N=46P-value?n (%)n (%)n (%)Age 9-17 years, ref. = 3-8 years58 (80.6)20 (76.9)38 (82.6)0.558Male, ref. = female31 (43.1)9 (34.6)22 (47.8)0.277Black race, ref. = white and others62 (86.1)22 (84.6)40 (87.0)0.783Parent’s education ≥ some college, ref. = high school or less40 (55.6)16 (61.5)24 (52.2)0.442Public health insurance, ref. = private insurance64 (88.9)24 (92.3)40 (87.0)0.488Smoker in household31 (43.1)8 (30.8)23 (50.0)0.113*Live attenuated influenza vaccine **Inactivated influenza vaccine?By Chi-square testTable 2. Differential Gene Expression in Response to Vaccination with Inactivated Influenza Vaccine (IIV) and Live Attenuated Influenza Vaccine (LAIV) Inactivated Influenza Vaccine (IIV)Live Attenuated Influenza Vaccine (LAIV)Gene NameNormalized Mean CountsFold ChangeLog2 Fold ChangeP-valueQ-valueNormalized Mean CountsFold ChangeLog2 Fold ChangeP-valueQ-valueDay 0Day 7Day 0Day 7CCL 22250.4666.40.30-1.760.0000.0001222.5982.80.80-0.310.4180.995CCL 7218.221.70.10-3.330.0000.000148.215.20.10-3.290.0000.000CRP0.00.310.83.440.4690.9644.00.00.01-6.770.0090.127CXCL 10194.5214.31.100.140.6990.964118.6297.52.501.330.0160.186CXCR 485358.265535.90.77-5.060.0050.09096750.569100.40.71-0.490.0240.208IFI 65583.35884.01.100.080.8910.9643132.510545.83.401.750.0000.007IFIT 35185.35437.81.000.070.6970.9643065.87878.82.601.360.0010.036IFNA 113.32.50.19-2.400.0140.17511.35.60.50-1.010.4490.995IL 12B13.91.70.12-3.020.0110.1633.65.51.500.620.6350.995IL 45.30.20.03-0.380.0010.03879.596.31.200.280.5970.995IL 833833.423295.40.69-0.540.0020.03830873.126617.80.86-0.210.3090.995MX 16148.16471.11.100.070.7070.9644289.68382.42.000.970.0220.208TNFSF 1029765.035952.31.200.270.1020.66522680.539467.11.700.800.0250.208NOTE: The two genes that are common between the two vaccine types are shaded in gray; bolded P-values indicate significance. Normalized mean counts obtained for each gene on Day 0 pre-, or Day 7 post influenza vaccination; fold change refers to the ratio of mean counts on Day 0 and Mean Counts on Day 7.Figure. Heat maps of RNA-seq responses to IIV and LAIVFigure legend. Heat maps representing differential expression of genes between Day 0 (pre) and Day 7 (post) vaccination based on P<0.05. IIV = inactivated influenza vaccine; LAIV = live attenuated influenza vaccine Supplemental Table 1. Inactivated Influenza Vaccine (IIV)Gene Name (alphabetized)Normalized Mean Counts D0 IIVNormalized Mean Counts D7 IIVFold ChangeLog2 (Fold Change)p-valueq-valueBAK12305.62568.21.100.160.5860.937BAX271.5305.41.100.170.8170.937BCL104.7143.001.560.1710.917BCL23889.43864.70.99-0.010.8900.937C34.24.51.100.080.9660.978CASP125139.125931.51.000.040.7850.937CCL22213.9660.10.30-1.750.0000.000CCL7221.321.50.10-3.370.0000.000CD244153.74973.21.200.260.3120.937CD362791.33276.61.200.230.4150.937CD46862.27146.91.000.060.8070.937CD40LG3424.43528.11.000.040.9010.937CD70237.4279.51.200.240.5910.937CD80519.7430.60.83-0.270.5970.937CD863285.23243.10.99-0.020.9130.937CD8A1197011149.10.93-0.100.5590.937CRP10.21.90.18-2.440.0440.348CRP4.830.63-0.670.4260.937CRP00.210.503.400.4890.937CXCL10173.2214.11.200.310.4960.937CXCL1127.115.40.57-0.810.3520.937CXCL132.93.41.200.240.9000.937CXCL26123.64170.50.68-0.550.0450.348CXCL926.943.81.600.700.3070.937CXCR488094.265696.90.75-0.420.0020.040DDX581810.22111.11.200.220.5340.937DEFA4348.3527.91.500.600.1170.713DEFA4947.61379.81.500.540.0750.487DEFA4527.7837.91.600.670.0490.349FADD896.3964.91.100.110.7650.937FASLG850.57970.94-0.090.7480.937FBXO96174.66474.91.000.070.7930.937FOXP3313.5296.50.95-0.080.8300.937GIF001.000.001.0001.000GNLY71971.1669610.93-0.100.5240.937GTPBP12400.923400.97-0.040.8430.937GZMA11902.311391.60.96-0.060.7160.937GZMB4115.23566.30.87-0.210.5040.937GZMK4570.84439.60.97-0.040.8510.937GZMK26498.725813.20.97-0.040.8240.937GZMK10801.510506.30.97-0.040.9150.937HLA-A60036403.91.100.090.6820.937ICAM1336.7233.90.69-0.530.2850.937IFI617425.220244.41.200.220.2820.937IFI65298.75812.11.100.130.7300.937IFIT37951.992341.200.220.3130.937IFIT34808.45396.91.100.170.4480.937IFITM187940.886215.90.98-0.030.7550.937IFNA113.83.10.23-2.140.0210.254IFNA21.532.101.060.3210.937IFNAR11466315309.31.000.060.7610.937IFNG207.82701.300.380.6060.937IL105.94.50.75-0.410.8840.937IL12A113.8141.91.200.320.5540.937IL12B14.31.70.12-3.100.0090.133IL1312.36.10.50-1.010.3160.937IL15806790.30.98-0.030.9800.980IL17A00.4InfinityInfinity0.2200.937IL1A111.182.10.74-0.440.5150.937IL1B4786.23299.60.69-0.540.0390.348IL223.425.31.100.120.7680.937IL218.412.41.500.560.3950.937IL21R612.9603.70.98-0.020.8830.937IL220.100.000.000.5380.937IL22RA2001.000.001.0001.000IL23R148.6121.70.82-0.290.5090.937IL24001.000.001.0001.000IL270.800.05-4.340.1730.917IL28A10.212.91.300.340.5860.937IL28A42.265.81.600.640.3360.937IL28B001.000.001.0001.000IL28B2.762.201.140.2600.937IL485.778.50.92-0.130.5280.937IL44.40.20.04-4.800.0030.051IL6260.7173.10.66-0.590.2470.937IL83379723056.20.68-0.550.0020.040IRF73203.333041.000.040.8960.937MS4A127280.528659.71.100.070.7450.937Supplemental Table 2. Live Attenuated Influenza Vaccine (LAIV)Gene Name(alphabetized)Normalized Mean Counts D0_LAIVNormalized Mean Counts D7_LAIVFold ChangeLog2 (Fold Change)p-valueq-valueBAK12330.22473.2Fold Change0.090.8160.992BAX222.8222.31.1000.9920.992BCL107.19.81.000.470.5360.992BCL23848.33449.21.40-0.160.5850.992C32.91.90.90-0.610.5520.992CASP122520.229822.60.650.410.2700.992CCL21275.71146.21.30-0.150.5910.992CCL7133.416.10.90-3.050.0000.001CD243576.63814.90.120.090.8570.992CD362884.13557.71.100.30.4820.992CD46747.76386.91.20-0.080.7620.992CD40LG2934.82769.50.95-0.080.8440.992CD70250.1201.80.94-0.310.6560.992CD80406.3376.10.81-0.110.7910.992CD863270.83068.10.93-0.090.8170.992CD8A10804.79381.20.94-0.20.6670.992CRP3.61.60.87-1.170.1940.992CRP2.13.50.440.720.6700.992CRP001.6001.0001.000CXCL10239.1740.31.001.630.0060.077CXCL1120.827.23.100.390.5690.992CXCL1344.61.300.210.8580.992CXCL25390.14123.51.20-0.390.2350.992CXCL958.267.40.770.210.6770.992CXCR489596.4681611.20-0.390.0780.502DDX581441.12555.20.760.830.0570.461DEFA4606457.91.80-0.40.5290.992DEFA41578.31201.80.76-0.390.5120.992DEFA4811.9641.60.76-0.340.6720.992FADD759.9736.40.79-0.050.8850.992FASLG802.4723.60.97-0.150.9380.992FBXO95202.353860.900.050.9010.992FOXP3233.1245.41.000.070.9110.992GIF001.1001.0001.000GNLY7674168764.81.00-0.160.6160.992GTPBP12336.62423.20.900.050.9800.992GZMA12295.412395.31.000.010.7580.992GZMB3885.83523.11.00-0.140.8360.992GZMK5078.24756.20.91-0.090.8540.992GZMK27545.527617.50.9400.9340.992GZMK10679.510762.61.000.010.8500.992HLA-A5074.45439.41.000.10.8810.992ICAM1279.8309.61.100.150.9820.992IFI615740.632364.31.101.040.0030.048IFI63939.211707.12.101.570.0000.001IFIT3703915182.83.001.110.0010.017IFIT34026.98853.42.201.140.0010.017IFITM182902.992032.42.200.150.6480.992IFNA1101.41.10-2.830.0600.461IFNA21.46.20.142.120.2200.992IFNAR113260.613973.34.400.080.9590.992IFNG287.3285.61.10-0.010.7300.992IL104.33.20.99-0.440.4670.992IL12A111.91300.730.220.6130.992IL12B3.25.61.200.80.5520.992IL1312.275.70E-01-0.80.2920.992IL15779.78251.10.080.9090.992IL17A01InfinityInfinity0.2700.992IL1A47.456.21.20.250.7410.992IL1B2648.23210.31.20.280.6530.992IL220.222.51.10.160.8570.992IL215.391.70.760.3290.992IL21R552.3539.49.80E-01-0.030.9810.992IL2200101.0001.000IL22RA200101.0001.000IL23R137.3140.710.030.9270.992IL2400101.0001.000IL2723.61.80.860.6920.992IL28A4.211.52.71.440.1170.700IL28A68.755.88.10E-01-0.30.4750.992IL28B01.7InfinityInfinity0.0740.502IL28B5.42.24.10E-01-1.30.3320.992IL474.4107.21.40.530.4070.992IL44.24.19.80E-01-0.030.9740.992IL6244.9169.36.90E-01-0.530.3210.992IL830023.327470.29.10E-01-0.130.4220.992IRF726314675.51.80.830.0400.373MS4A123286.621846.59.40E-01-0.090.7840.992MX14672.98639.41.80.890.0100.125PRF117064.716902.59.90E-01-0.010.9620.992PRF119223.218977.79.90E-01-0.020.9580.992PRF121056.220213.19.60E-01-0.060.8340.992PRKRA46934543.99.70E-01-0.050.8820.992TGFB16866.17438.11.10.120.9080.992TGFB212.58.16.40E-01-0.640.4240.992TLR3287.6205.27.10E-01-0.490.3960.992TNF1152.51108.69.60E-01-0.060.8220.992TNFSF1024990.144476.41.80.830.0140.150VEGFA1989.91529.77.70E-01-0.380.3630.992 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download